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The goal of this project is to study the potential applications of silver nanoparticles 
(SNPs) in the medical device and pharmaceutical industries. Bone cements have been used in the 
orthopedic surgeries for many years to anchor prosthetics while filling up the spaces between the 
prostheses and bone. Antibiotics are an active component of bone cements but the increasing 
bacterial resistance to these antibiotics and difficulty of shaping and molding the bone cements 
increases the need for new antimicrobial biomaterials.     
Adult stem cell based regenerative therapies have been one of the most widely researched 
areas of tissue engineering. This is due to the recent success of in vitro differentiation of stem 
cells and a high demand to replace damaged organs and tissues from autologous and allogenic 
source using regenerative methods. In bone regeneration, growth fact based surgeries have lead 
to the calcification bones outside the surgical site. Here, we test a SNP based osteogenic drug 
delivery system, both in vitro and in vivo, that will provide clinicians and health care providers 
control of the activation stem cell differentiation leading to the formation of bone.   
We will evaluate the in vitro osteogenic differentiation of human adipose stem cells with 
light mediated miR-148b-Nanoparticle conjugates. We will functionalize SNPs with osteogenic 
miR-14b with a UV sensitive photocleavble group and a TAMRA 563 molecule. The SNP-miR-
148b conjugates will be added to hASCs and activated with UV radiation that will release the 
miR-148 from the conjugate. The released miRNA will differentiation stem cells into osteoblast. 
The upregulation of early and late stage osteogenic differentiation markers like ALPL, OCN and 
Runx2 will be analyzed by qRT-PCR and histological stains (ALPL stain and Alizarin Red).  
Also, we will evaluate the healing of critical size mouse calvarial defects with light 
activated miR-148b-Nanoparticle conjugates. After testing the in vitro differentiation of hASCs, 
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we will evaluate the healing of calvarial size defects with SNP-miR-148b. A 4 mm critical size 
defect (non-healing) will be drilled on the skull of mice and filled with non-osteogenic 
Polycaprolactone (PCL) scaffolds. Prior to implantation, the scaffolds will be seeded with 
hASCs, transfected with SNP-miR-148b conjugates and radiated with UV. The healing of the 






Chapter 1. Background and Introduction to Drug Delivery Systems 
 
1.1 Noble Metal Nanoparticles: Properties & Applications  
 The use of nanostructures, notably colloidal nanoparticles, in molecular diagnostics and 
drug delivery has emerged and increased significantly within the last decade[1]. Nanostructures 
are amenable to molecular detection, intracellular diagnostics and therapeutic applications due to 
their sub-microscopic dimensions (<1 um) and the often unique properties which emerge at these 
dimensions, and which differ from those of the bulk materials. Due to corresponding size-scales, 
nanostructures easily interface with biological molecules, such as nucleic acids and proteins[1]. 
Among the nanostructures which are increasingly being used as biological sensors and delivery 
vehicles for therapeutic agents, nanoparticles are of particular interest. Beneficial characteristics 
of metallic nanoparticles include tunable size, shape, and functionality attributes; relative ease of 
fabrication via „wet chemistry‟ techniques[2]; large surface area-to-volume ratio; simple surface 
functionalization (via sulfur-metal linkages on noble metal nanoparticles) [3, 4], and enhanced 
stability of attached macromolecules such as nucleic acids[4, 5]. 
Metal nanoparticles, typically in the range of 1-100nm in diameter, are attractive due to 
their unique electronic and photonic properties [2, 6, 7]. Noble metal (Au, Ag, Pt, and Cu) 
nanoparticles have accrued interest owing to a phenomenon unique to these nanomaterials, 
known as localized surface plasmon resonance (LSPR). LSPR occurs when a small spherical 
metal particle is subjected to an oscillating electric field, which causes the conduction electrons 
at the metal surface to oscillate collectively in response[7]. The local field enhancements 
attributed to surface plasmons have paved the way for many surface-enhanced spectroscopy 
techniques, including surface-enhanced absorption, fluorescence, photochemistry, and Raman 
scattering (SERS)[8]. These techniques have applications in chemistry, biology, and medicine.  
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Gold (Au) and silver (Ag) nanoparticles have been used extensively as biological sensors 
which take advantage of plasmon resonance to enhance detection of specific targets. Noble metal 
nanoparticle-based sensors benefit from the extreme sensitivity of LSPR spectra to 
environmental changes[9]. Application of metal nanoparticles is not limited to molecular 
detection: recently, gold nanoparticles (GNPs), and to a lesser extent silver nanoparticles (SNPs), 
have been harnessed as delivery vehicles for therapeutic agents, including antisense 
oligonucleotides[10-12] and other small molecules[4, 13, 14]. Small metal nanoparticles offer 
many advantages as drug carriers, including high-density surface ligand attachment, 
transmembrane delivery without harsh transfection agents[10], protection of the attached 
therapeutic from degradation[5, 11, 15], and potential for improved timed/controlled intracellular 
release[15]. The photophysical properties of noble metal nanoparticles[16] may potentially bring 
these materials to the forefront of drug delivery, enabling targeted delivery, spatiotemporally 
controlled (photo-)release, and delivery confirmation via imaging.  
1.1.1 Localized Surface Plasmon Resonance (LSPR) 
 Localized surface plasmons (LSPs) are excitations of the conduction-band electrons of 
sub-wavelength conductive nanoparticles coupled to an incident electromagnetic field (i.e. 
light)[17]. The noble metals in bulk form have overlapping conduction and valence electron 
bands which do not allow electrons to move relatively freely based on their energy state. [16] 
The metal nanoparticles have number of electrons large enough to be characterized by properties 
differing from those of single atoms, yet too few electrons to reflect the properties of the bulk 
metal which have close lying (not overlapping) conduction and valence bands (Figure 1.1). 
Surface plasmons are based mostly upon the oscillations of free electrons within the conduction 
band that occupy energy states immediately above the Fermi level[16, 18], where the Fermi level 
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is the outer boundary of electron energy states at absolute zero temperature. Electrons which 
exist in energy sates above the Fermi level are available for conduction. The optical properties of 
noble metal nanoparticles are mostly influenced by the electron oscillations, however, the 
movement of bound electrons can also contribute to the plasmon spectra of these resonant 
particles[7]. Localized surface plasmon resonance (LSPR) occurs when the charge-density 
oscillations of the conduction electrons on the surface of metal nanoparticles [6] attain resonance 
conditions. Resonance modes arise due to the fact that the curved surface of the nanoparticle 
exerts an effective restoring force on the oscillating electrons[17]. Under resonance conditions, 
the nanoparticle acts as an electric dipole, resonantly absorbing and scattering electromagnetic 
fields[17]. In 1908 Mie applied Maxwell‟s equations to sub-wavelength conductive spheres (Mie 
Theory[18]) in order to describe the optical properties of metallic nanoparticles. Mie theory 
describes and quantifies the extinction spectra (the combination of absorption and scattering) of 
spherical particles of arbitrary size in various dielectric media[7]. Since the advent of Mie theory, 
other models have been developed to further and more precisely describe the electronic 
properties of metal nanoparticles, especially non-spherical particles[19]. However, Mie theory 
remains an important model for describing the size-dependent optical properties of spherical 
particles in solution. 
 Localized surface plasmons (LSPs) have a strong affect on absorption and scattering of 
light and this attribute contributes to bright colors observed in solutions of colloidal noble-metal 
nanoparticles. The plasmon resonant absorption spectra of Gold (Au) and silver (Ag) 
nanoparticles lie within the visible region[16],  AuNP and AgNP  are characterized by a wine-red 
color, with a plasmon band centered around 520nm[20] and by a yellow/green color, with a 
plasmon band around 400-420nm dependent on particle size[21] respectively. Additionally, this 
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plasmon frequency of the NP also depend on particle size, shape, surface state, interparticle 
distance, and the surrounding dielectric environment[6] and is used to determine the 
hybridization-induced coupling of DNA-functionalized gold and silver particles[9, 22, 23]. 
 
Figure 1.1 – Overlap of conduction and valence electron bands for metals: single atom, 
nanoparticles, and bulk metals. 
 
The plasmon resonance frequency describes the location at which absorption and 
scattering (both components of extinction) of light by metal nanoparticles are at a peak value 
based upon maximum amplitude of electron oscillations and interactions. According to Mie 
Theory, the extinction cross-section (Cext) of metal nanoparticles is comprised of both absorption 
(CA) and scattering (CS) components. Also the surface plasmon resonance frequency is largely 
dependent on particle size, and larger particles, dominated by multipole absorption and 
scattering, typically exhibit red-shifted (longer wavelength) extinction spectra[24]. For small 
metal particles (λ >> 2R where R is the particle radius), the extinction cross-section is dominated 
by dipole oscillations at the particle surface[24, 25] while for larger particles (2R comparable to 
incident wavelength λ)  the dipole oscillation mode is joined by higher multipole modes. For 
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small nanoparticles, the absorption part of extinction overtakes the scattering based on the 
nonradiative processes of plasmon decay[26] and as the nanoparticles increase in size, the 
scattering component contributes higher than absorption. As a result, the extinction spectra of 
metal nanoparticles, their absorption and scattering properties, can be tailored via control over 
particle size and shape.  
The strong optical properties of silver nanoparicles can be appreciated with direct 
comparison of its extinction coefficient. The extinction cross section of a 60nm silver colloid has 




 which is considerably higher than the cross-section of fluorescein 




[27]. These strong optical properties of metal nanoparticles 
are been increasing used advantageously in light scattering and surface-enhanced spectroscopy 
applications. 
1.1.2 Optical Properties of Silver Nanoparticles 
 Gold (Au) and silver (Ag) nanoparticles in the diameter range of ~2-100nm exhibit SPR 
spectra in the visible region, which are tunable and dependent on particle shape, size, 
environment, and interparticle distance. While gold nanoparticles have been used extensively in 
many of the applications previously discussed, silver nanoparticles have unique properties which 
make them a desirable alternative particle type in many cases. Silver nanoparticles (SNPs) are 
the strongest light scatterers of the noble metal particles[21, 28] and it is reported that the light 
scattering cross section of a silver nanoparticle is ~10 times greater than that of a similarly sized 
gold nanoparticle[21]. A noted previously, the extinction (light absorption and scattering) band 
of silver nanoparticles is due to free conduction electron oscillations and bound electron 
movements also contribute to the optical spectra[21]. Thus enhancement of absorption/emission 
of light by molecules near the silver particle surface is dependent on particle size and proximity 
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or overlap of the resonance (SPR) spectra with the absorption/emission bands of the molecular 
species.       
 The light absorption and scattering properties for silver nanoparticles of different sizes 
have been calculated in accordance with Mie Theory[18, 21]. For larger particle sizes (~50-
60nm), the scattering efficiency (Qsca) is high (≈5).  The silver particles in this size range scatter 
light at or above the physical metal surface but the scattering efficiency increases even higher to 
5.8 for size 70-80nm while maintaining surface plasmon resonance in the UV to visible range. 
This characteristic is ideal for traditional and red-shifted photocleavable compounds typically 
used as photo-caging compounds.  
 The light-scattering and field-enhancement properties of silver nanoparticles have led to 
an increased interest in their use as sensors, biological labels, and substrates for surface-
enhanced absorption, fluorescence, and photochemistry. Enhanced photochemistry has been 
predicted on silver surfaces, and silver nano-materials comprise the best enhancing substrate 
found to date[29]. Silver nanoparticles have high extinction coefficients[21, 30] along with low 
SPR frequencies (near-UV range) which make these particles particularly appropriate for studies 
of enhanced photochemistry of photoreactive moieties sensitive to UV irradiation.  
1.2 Silver Nanoparticle Synthesis 
 A variety of methods are available for the production of nanoparticles within a specified 
size distribution[2]. These include reduction of metal ions via chemical capping agents to form 
metal nanoparticles in solution, vacuum deposition, electron-beam (EB) lithography, laser-
ablation (photo- and radio-lytic reduction of metal ions), and electrodeposition (electrochemical 
deposition of nanoparticles)[6]. Spherical noble-metal nanoparticles for applications such as 
delineated herein are commonly prepared via „wet chemistry‟ procedures, where „clusters of 
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metal atoms… are formed in the presence of a surface-capping ligand‟[2]. The capping 
ligand[2], whether a hydrophobic ligand, a charged ligand, or a polymer stabilizing agent, serves 
to stabilize individual nanoparticles and prevent aggregation via particle-particle repulsion. The 
wet chemistry synthesis procedures are often simple and practical in the tunable synthesis of 
spherical particles of sufficiently narrow size distribution.  
1.2.1 Reduction Methods 
SNP can be produced by reducing agents such Sodium tetrahydridoborate NaBH4[31], 
HCHO/NaOH/Na2CO3 [32]
 
, a combined reduction by tri-sodium citrate and formaldehyde 
sulfoxylate (SFS)
 
[33], tetrakis hydroxymethyl phosphonium chloride, citric acid hydrazine 
hydrate and solvents like DMF, Ethylene glycol.  
In 1979, silver sols were prepared by reduction of silver nitrate (AgNO3) in an excess 
solution of NaBH4[34]. The solutions of silver salts were mixed rapidly and vigorously in order 
to aid monodispersity. Pyridine molecules adsorbed on the silver sol particles caused intense 
Raman scattering. The sols were yellow and displayed a single visible extinction band near 400 
nm by Raman spectra. The silver particles were substantially smaller than the wavelength of 
light and as indicated by transmission electron microscopy, the size of the particle diameter was 
roughly in the range 1-50 nm [31]. The sols were stable and there was no precipitation or change 
in color on standing for several weeks. 
Formaldehyde can also be used as a reducing agent for preparing nanoscale silver 
particles. In this synthesis, silver nitrate solution is used as the source of ion. The surfactant 
polyvinyl-pyrrolidone (PVP), a protective agent, is then added to AgNO3 and the metal is 
reduced using a formaldehyde solution. To increase the rate of the reaction, pH is increased by 
the addition of an alkaline solution consisting of NaOH and/or Na2CO3 which results in a faster 
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reduction. This synthesis produces well-dispersed spherical shaped crystalline silver particle with 
7–20 nm size [32]. 
The stoichiometric reaction of this process can be summarized as follows: 
2Ag
+
  + HCHO + 3OH
−
                 2Ag + HCOO
− 
 +  2H2O                                         (1) 
2Ag 
+
  + HCHO +  OH
−
                     Ag + HCOOH +  1/2H2                                                   (2) 
Direct large-scale synthesis of SNP is conducted by various reduction chemical methods 
but using mild reducing agent, such as formaldehyde SFS provides good particle morphology 
and results in fine silver powder [33].   
In this method for the synthesis of SNP, an aqueous solution of tri-sodium citrate was 
added to an aqueous solution of silver nitrate. The drop-wise addition of aqueous sodium 
formaldehyde sulphoxylate and continuous stirring at room temperature formed a dark gray 
precipitate, which can be filtered off, washed with methanol and dried. Scanning Electron 
Microscopy (SEM) images indicate 30-50 nm spherical and agglomerated SNP due to the 
presence of surfactants/capping agents. 
1.2.2 Sol-gel Process 
The sol-gel technique is low temperature method for synthesizing organic or inorganic 
amorphous materials. It is based on hydrolysis and condensation reactions of organometallic 
compounds in alcohol solutions [35]. Many metal particles including gold [35, 36], copper [37], 
platinum, palladium [38] and silver [39] have been prepared in glassy matrices by the sol-gel 
method. 
For the creation of stable silver metal nanoparticles, AgNO3 is dissolved in the precursor 
sol that contains TetraEthoxy OrthoSilane (TEOS) and Methyl- TriEthoxy OrthoSilane 
(MeTEOS). Soda lime glass slides can be added in the precursor sol and AgCl containing sol gel 
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glasses are prepared.  When these films are heated to 600
0
C, stable silver metal nanoparticles are 
created that are 2-21 nm in size as calculated from X-ray diffraction [34]. This method produces 
large clusters of SNP of inconsistent size.    
1.2.3 Chemical Vapor Synthesis (CVS) 
Recently, CVS has become popular tool for producing highly pure, ultrafine and un-
agglomerated nano-crystalline powders. Many chemical vapor methods have been developed 
which take advantage of various conditions to prepare SNP. Some of the various CV methods 
include sonic-jet corona discharge [40, 41], electrospray-assisted CVD process [42]
 
and 
supersonic nozzle expansion method [43]. 
In sonic-jet corona discharger method, sonic-jet corona ionizer is heated by an infrared 
furnace and an electric field is applied. Charged nanoparticles are deposited on the substrate 
electrode in the CVD nanoparticle generator by the help of an electric field after ionized 
molecules are introduced in the furnace. 
The electrospray-assisted CVD reactors consist of an electrospray source, a tube-type 
CVD furnace and an electrostatic sampler. Liquids are supplied into the capillary by a high 
resolution syringe pump and a high voltage is applied to the capillary through a high DC voltage 
source. Electric current carried by electrospray and the stability of the spray is monitored 
visually, in this process changes in the voltage could result in multiple jets of the liquid. NPs 
were produced by the thermal decomposition of the precursor vapors in the reactor. 
Recently, supersonic nozzle expansion method (rapid decrease in temperature and 
density) with corona discharge ions was used for synthesizing SNP. In the particle formation 
step, the high cooling rate of condensable vapor results in a large supersaturation for the 
nucleation rate. The nucleation and growth of the SNP occurs after the expansion region in the 
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supersonic nozzle, where corona discharge ions are applied, as the nuclei for nanoparticles, to 
impart charge and modulate agglomeration. 
Overall, CV methods produce NP from the vapor phase in a well controlled temperature 
zone of a hot wall reaction tube. These processes typically produce agglomerated NP due to their 
Brownian coagulation in the CVD reactor. Although latest CVD methods have produced 
nonagglomerated, smaller sized and charged nanoparticles [43]. 
1.2.4 Biological Approach 
With an increased demand to develop clean, nontoxic and environmentally friendly NP 
synthesis methods, many researchers have started looking at biological systems for inspirations 
[44]. There are many examples both in the plant and animal kingdom of unicellular and 
multicellular organisms that produce inorganic materials either intra- or extracellularly [45, 46]. 
Some of them include magnetotactic bacteria (synthesize magnetite nanoparticles)[47, 48], 
diatoms (synthesize siliceous materials) [49, 50], S-layer bacteria (produce gypsum and calcium 
carbonate layers) [51, 52] and fungus Verticillium (synthesize aqueous Ag+ ions) [53]. 
The biological synthesis of silver-based 200 nm crystals in the periplasmic space of 
Pseudomonas stutzeri AG259 was reported in 1999 [54, 55]. This bacterium strain was originally 
isolated from silver mine[55]. In this method, the cells are cultured in the presence of high 
concentrations of silver salts. They are then harvested, fixed, distilled and polymerized. Ultrathin 
sections are stained and visualized under microscope.  
There are many other methods of synthesizing SNP including genetically engineered 
human L subunit ferritin [56], high pressure spurting[57], plasma spray methods [58], 
supercritical fluids (SCFs) [59] and etc. Although many of these methods have succeeded in 
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synthesizing nonagglomerated, pure, small size and stable SNP, there still exists a room for 
improvement in the design of polymer based SNP synthesis.   
1.2.5 Biomass Mediated SNP Synthesis 
Our choice of SNP synthesis method is related to the design requirements for chronic 
indwelling medical device coatings, effective antimicrobials and use as drug delivery vehicles. 
Based on design requirements we have selected one of the chemical reduction methods using 
formaldehyde as a reducing agent, in an alkaline NaOH solution to reduce AgNO3. This is a cost-
effective and industry applicable reduction that occurs at room temperature. The addition of 
hydroxypropyl cellulose (HPC), a hydrophilic polymer derived from biomass, acts as a template, 
[60] stabilizes the particle and provides a mechanism for concentration and purification. HPC is 
a thermo-responsive compound and flocculates at elevated temperatures which facilitate 
synthesizing concentrated, highly pure and polymer compatible SNPs with increased 
permeability [61].  The thermally mediated flocculation and concentration step allows the bulk 
residual reaction by-products to be removed by serial pelleting, washing and resuspension 
(Figure 1.2). 
1.3 Characterization of Nanoparticles 
Many analytical methods have been published to characterize and confirm the presence 
of nanoparticles in the polymers. These methods outline the chemical composition and physical 
characteristics of the nanomaterials [62].  
1.3.1 Atomic Force Microscopy (AFM) 
Initially, AFM was introduced as imaging tool [63] as it provides high resolution, three-
dimensional images and helps in detailing surface topography. Recently it has been widely used 
for the investigation of nanoparticle-doped materials and surface biofouling. It has also been 
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used to examine nanoparticle deposition on silicon substrates, and the morphology of these 
nanoparticles was studied [64]. Several publications have also used AFM to confirm the 
morphology and size distribution of silver nanoparticles [65]. It has several advantages terms of 
resolution, speed and ease of sample preparation when compared to other when compared to 
cryo-electron microscopy and X-ray crystallography techniques [66]. For our synthesis AFM has 
been used to determine the organization, shape and size of SNP. 
 
Figure 1.2. Process flow diagram of the biomass mediated reduction and purification process. 
1.3.2 Transmission Electron Microscopy (TEM) 
TEM is also an analytical tool for determining the morphology and arrangement of 
nanoparticles comprised materials. Several studies have utilized TEM as a characterization 
method for different nanoparticles including SNP [67]. SNP will be visualized by TEM [68] and 
serves as one of our major characterization tools. It enables us to visualize and characterize the 
morphology and distribution of SNP embedded in the biocompatible polymer-based coatings.  
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1.3.3 Scanning Electron Microscopy (SEM) 
SEM is also an analytical tool that uses a focused beam of high-energy electrons to 
generate a variety of signals at the surface of solid specimens. Unlike TEM, it allows the surface 
structure of the sample to be studied at high resolutions, enabling characterization of external 
morphology (texture), chemical composition, and crystalline structure and orientation of solid 
materials. 
1.3.4 UV-Visible Spectroscopy 
           UV-visible spectroscopy is a very simple and quick method for characterizing noble metal 
nanoparticles and is mostly used to confirm the presence of nanoparticles in a liquid. It is not 
capable of providing detailed information regarding NP size distribution when compared to 
microscopy based analysis techniques but is a semi-quantitative method for determining the 
presence and size distribution of NP. UV-Vis can also serve as an indicator of material 
deterioration and is a qualitative method for indicating the presence of nanoparticles in the 
polymer. 
The breadth of the UV-visible chromatogram peak, obtained from SNP, will indicate the size 
distribution of SNP but morphology has to be confirmed using different imaging methods. The 
sample preparation for this method is very simple and will enable us to monitor the effectiveness 
of the silver nanomaterial and adhesion of SNP to the biocompatible polymer. 
1.3.5 Dynamic Light Scattering (DLS) 
 
 Dynamic light scattering (DLS) is a technique by which the size distribution of small 
particles in solution (a colloid)  may be quantified from changes in a light field (frequency shifts, 
polarization changes) due to its interaction with the colloidal  system[69].  The information 
gathered by DLS is related to the light scattering properties of suspended solutes. Dynamic light 
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scattering may be used to measure the diffusion coefficient for solute molecules/particles, which 





           (3)   
where  is the Boltzmann constant (in J K
-1





T is the temperature in Kelvin, and r is the hydrodynamic (or Stokes) radius. The hydrodynamic 
radius is the apparent radius of a molecule/particle in solution, based on their measured rates of 
diffusion. Dynamic light scattering analysis of a colloid also provides a measure of the 
polydispersity (size distribution) of the particle solution. 
 Dynamic light scattering instruments may also be used to measure zeta potential 
(electrokinetic potential at the effective shear plane between the moveable and non-moveable 
part of the double layer[70]) of colloids. Zeta potential of solutes may be determined from the 
light scattering properties of molecules/particles moving within an applied electric field  
(electrophoretic light scattering)[70]. Zeta potential is an important indication of colloid stability 
and biomolecule adhesion onto the particle surfaces. DLS will been performed herein using a 
Malvern ZetaSizer Nano ZS (Malvern, Worcestershire, UK). 
1.3.6 Silver Content Analysis 
Determining the silver content in these NP composites is critical to the design of effective 
antimicrobial scaffolds and drug delivery vehicles. The silver content of scaffolds and the 
oligonulceotide-SNP targeting drug will assist in tuning the silver concentration to achieve 
maximum efficacy for scaffolds and optimum/noncytotoxic drug dosage respectively. Some of 
the methods that comply with our needs and are available to use are Thermogravimetric Analysis 
(TGA) and Inductively Coupled Plasma-Optical Emission Spectrometer (ICPOES).  
 
 15 
1.3.6.1 Thermogravimetric Analysis (TGA) 
TGA is commonly used in research and testing to determine the mass of inorganic and 
organic components in materials by measuring the characteristic of weight change of a material 
in relation to changes in temperature. Synthesized copper, silver and alumina nanocomposites 
have been characterized by thermo gravimetric analysis to study the composition of the metal 
nanoparticles‟ percentage contained in the polymer/composite [71]. The weight loss curve, after 
curve smoothing and other operations, can be used to find the point of deflection.  
For our SNPs, TGA serves as one of our major characterization tools to determine the 
percent of silver particles in the scaffolds. Additionally, TGA can also provide information 
related to the spatial conformation of the silver content and the chemical state of the Ag atoms in 
the SNP solution [72].  
1.3.6.2 Inductively Coupled Plasma Optical Emission Spectrometer (ICPOES) 
ICP-OES (Inductively Coupled Plasma-Optical Emission Spectrometer) is one of the 
most common analytical methods for determining silver content as it has high sensitivity, high 
precision, and capable of determining range of metals and several non metals at concentrations 
range from a several percent to ppb levels [73]. 
In this study, ICPOES analysis is used to monitor the release of SNP particles and ions 
from the scaffolds after being treated with bacteria. The analysis enables us to quantify the 
release of SNP from the coatings in a time-based study and plot the release profile of SNP. 
1.3.6.3 Oligonucleotide Coverage Quantification 
miRNA coverage on functionalized SNP-conjugates was quantified via fluorescence-
based measurements of particle-released oligonucleotide samples while the silver content of 
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HPC-SNP pellet was quantified via inductively coupled plasma optical emission spectrometry 
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1.4 Applications of Silver Nanoparticles:  
1.4.1 Silver as an Antimicrobial Agent 
Silver is an oligodynamic antimicrobial compound, meaning that exposure to relatively 
low concentrations of the metal can result in substantial reduction of viable microbial organisms. 
The ionic form of the compound, Ag
+
, has been identified as the primary active agent [74], 
although some recent research indicates that the nanoscale metal form of the compound may 
have some unique antimicrobial attributes [75]. Various silver compounds have been used as 
antimicrobial agents in many healthcare related applications including; pathogen control, 
prophylaxis and therapeutic treatments. Salts [76-79], zeolites [80-82] and thin film metal 
coatings [83] have demonstrated some utility as silver ion sources for medical devices, but 
concerns regarding cost, performance and safety have limited the broader adoption of these 
delivery vehicles in indwelling device applications.  
1.4.1.1 Silver Bearing Salts 
Silver bearing salts, specifically, silver nitrate, silver halides and silver sulfadiazine 
(SSD) have been used as an antimicrobial agent in applications ranging from burn treatment to 
catheter systems. The exact mechanism of silver and its salts on the microbes is still not known 
but the possible mechanism of metallic silver, silver ions and silver nanoparticles have been 
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suggested after looking at the morphological and structural changes in the bacterial cells [84]. 
The silver interacts with thiol group compounds found in the respiratory enzymes of bacterial 
cells and binds to the bacterial cell wall and cell membrane, inhibiting the respiration 
process[85]. In the case of E. coli, it acts by inhibiting the uptake of phosphate and releasing 
phosphate, mannitol, succinate, proline and glutamine from E. coli cells [55, 86-89]. The 
replication of DNA is effectively conducted when the DNA molecules are in relaxed state and 
loses its replication ability when in condensed form. When the silver ions penetrate inside the 
bacterial cells, DNA molecule condenses reducing the rate bacterial replication.  It has also been 
reported that heavy metals react with proteins by interacting with the thiol group deactivating 
proteins[84].  
Silver nitrate is a highly water soluble compound that has been used historically in the 
treatment of burns and as a prophylactic to reduce the transmission of gonorrhea to new born 
infants during birth[90]. Silver nitrate has not been used extensively as a device delivered 
antimicrobial, as its high water solubility and low chemical and thermal stability result in 
relatively short duration of release and challenges in device design and incorporation. 
Additionally, studies comparing wounds treated with silver based antimicrobials have 
demonstrated that silver nitrate, compared to other silver forms, significantly retards the re-
epithialization and neovascularzation of wound beds [77, 91]. Two halide forms of silver; silver 
chloride and silver bromide, have been explored as sources of Ag ion for medical device coatings 
but poor solubility and poor thermal stability, compared to other ionic forms, have limited their 
broader use in medical device applications [77, 92, 93].  
In the 1970‟s silver sulfadiazine (SSD), a salt derivative of a sulfa drug compound, was 
characterized and formulated for use in topical creams and ointments to provide a more 
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efficacious and stable ionic silver delivery option for the treatment of burns and other chronic 
wounds[94]. More recently, the use of SSD as an active agent has been expanded beyond topical 
applications including incorporation in devices such as central line catheters and professional 
wound care dressings and packings [79, 95]. The mechanism of action of SSD is distinct from 
silver nitrate and silver halide compounds as it acts by disrupting the organism‟s cell wall and 
releasing ionic silver through interaction with physiological solutions[94]. The compound‟s poor 
solubility in aqueous environments and chemical instability has prevented its broader use in 
device based delivery systems. While SSD is less cytotoxic than silver nitrate, it is still 
significantly more toxic than many other commonly used antiseptics and antibiotic compounds, 
it can prolong wound healing and has been implicated in cases of renal failure [96-98].  
1.4.1.2 Silver Zeolites and Glasses 
Silver bearing zeolites and glasses, which entrap Ag ion in ceramic crystal or amorphous 
glass carriers, are the second most common source of Ag ion used in the manufacture of medical 
devices. Both the zeolites and glass compounds are relatively large, ~2-200m hydrophilic 
particles, but each compound has distinctly different mechanisms for silver ion release. Silver 
zeolites are typically composed of mesoporous aluminosilicate or zirconium phosphate which 
entrap Ag ion within the nanoscale pores in the crystal structure. Zeolites release Ag
+
 into 




, ions which are 
ubiquitous in physiological environments. Exposure of high salinity physiological solutions 
typically results in an initial bolus of Ag ion release and rapid exhaustion of the bioavailable 
silver ion within the device. The micron scale ceramic carrier is largely inert and not 
biodegradable, end of life cycle analysis indicates that substantial amounts of silver in zeolites 
are not bioavailable and remain sequestered within the crystal structure. [82] 
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Unlike zeolites, silver glass particles are amorphous and are typically composed of 
unstable, silver doped silica and phosphate compounds [99, 100]. Silver doped glass or 
“bioglass”, as it is often referred, releases silver ion through a surface mediated corrosion 
process. The relatively large size of the particles and the chemical stability of the silver oxide 
form in glass tend to reduce the bioavailability of silver ion. Thus requiring high concentrations 
of bioglass, in the parts-per-thousand range, to achieve reasonable microbial kill rates[100]. The 
large size and slow corrosion rate of the bioglasses limit their use in bioresorbable thin film 
coatings. Zeolites and bioglasses share some common features; the silver in both classes of 
compounds tend to photo-reduce on exposure to light, reducing the amount of bioavailable 
silver[101]. Also, the hydrophilic nature of the particle surface reduces the solubility of both 
types of materials in hydrophobic polymer and solvent systems.  
1.4.1.3 Other Silver Sources 
Bulk metal silver coatings have been used to impart antimicrobial properties to several 
types of medical devices including; catheters, endotracheal tubes and heart valves.  The silver 
coated heart valve device produced by St. Jude Medical, is notable in that the device‟s bulk silver 
coating promoted the onset of endocarditis in tissue immediately in contact with the valve 
material leading to device rejection[102, 103].  This unexpected cytotoxicity associated with 
long term exposure to bulk silver coated implants has limited its use to device designed for acute 
applications.  
The recent commercial availability of metallic, nanoparticle silver polymer additives has 
created a renewed interest in silver based antimicrobials [95, 104, 105]. Advances in synthetic 
techniques used for particle production have greatly reduced cost, improved yields, and 
diversified the available particle chemistries and morphologies [44, 106-110]. Shapes such as 
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rods, spheres, pyramids and other polygons can be combined with a myriad of chemical 
functionalities to create a wide window of particle solubility and reactivity. This highly flexible 
nanoscale form of metallic silver potentially addresses many of the limitations of ionic silver 
delivery systems that have restricted their use as an antimicrobial in the design and manufacture 
of chronic indwelling devices.    SNP provides a thermally, chemically and photostable reservoir 
of metal atoms that are uniquely suited to polymer composite formation while remaining 
available for conversion to the active ionic compound upon exposure to physiological solutions. 
SNP show efficient antimicrobial property compared to other salts due to their extremely large 
surface area, which leads to better contact with microorganisms [84]. 
Our novel biomass medicated synthesis and concentration/purification method allows for 
the synthesis of high purity, biocompatible, nanomaterial powders and colloidal solutions with 
tunable chemical properties. This SNP synthesis method produces metal nanoparticles with a 
size distribution from 25-75 nm. By careful choice of capping surfactants and 
bioresorbable/biocompatible stabilizing agents the silver ion release profile and particle 
dissolution rate can be predictably modified, allowing fine control of the antimicrobial efficacy 
and particle lifetime in a physiological environment. 
1.4.2 Nanoparticle as Drug Delivery Vehicles 
 Functionalized metal nanoparticles have accrued significant interest as drug delivery 
vehicles and potential substrates for targeted and controlled release of therapeutic agents in vivo. 
Protein-based and, of interest herein, nucleic acid-based drugs are in need of novel delivery 
technologies which can enhance delivery, prolong lifetime, enable precise targeting, improve 
efficacy, and minimize side effects[15]. Nanoparticles provide a promising and exciting solution, 
bringing to the table improved delivery and stability characteristics, as well as the potential for 
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external control (thermal, photo-thermal[4], light-activated[111]) over drug release and activity 
in vivo[15]. Various nanoparticle formulations have been used for delivery of biomolecules such 
as small molecule therapeutics[13, 15, 112, 113], proteins[15, 113], nucleic acids[3, 10-12, 14, 
15, 114, 115], antisense oligonucleotides [10, 12], and siRNAs [11, 116, 117].  
Nanoparticles have been shown to protect immobilized biomolecules from degradation 
(notably nucleic acids[5]), thus prolonging their active lifetime[15]. Protection of nanoparticle-
immobilized nucleic acids from degradation by nucleases has been partially attributed to the high 
local salt concentration which accompanies dense nucleic acid packing on the particle surface. 
High salt concentration is known to deactivate the enzymatic activity of DNase II[118], a 
principal agent of nucleic acid degradation in vitro. Other explanations for the stability of nucleic 
acids when attached to nanoparticles include steric hindrance of nucleases, protection of a 
surface-attached 3‟ oligonucleotide end from 3‟ exonucleases[119], and possible protective 
layers of positively-charged serum proteins which absorb to the highly-charged nucleic acid-
nanoparticle surface[10]. 
Biomolecule surface-functionalized nanoparticles not only possess characteristics of 
enhanced stability, but provide a means to deliver greater amounts of target therapeutic via high 
density surface coverage, often without requiring additional transfection agents for passage 
through the cell membrane[10]. Nanoscale delivery vehicles have been shown to enhance 
cellular uptake via facile endocytosis of small functionalized nanoparticles[113] mediated by 
scavenger receptors[120], intracellular trafficking of delivered therapeutics, and nuclear 
access[121], the later being an important process in gene expression based therapies. Beyond the 
their enhanced cellular uptake and their delivery of high drug concentrations, metallic 
nanoparticles are also attractive due to the possibility of controlling the release of the bound 
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therapeutic molecules from the particle surface. The ability to attach ligands via specific 
interactions to the metal nanoparticle surface offers a high degree of engineering precision[15] 
with the potential for ligand/receptor targeted delivery[14] and controlled release of the particle 
payload. 
The potential benefits of noble metal nanoparticles (NP) in delivery applications include 
readily tunable morphology, ease of bulk synthesis, large surface area-to-volume ratios and 
robust functionalization chemistries[2]. Additionally, metal nanoparticles fulfill the core 
requirements as drug delivery vehicles by offering high-density surface ligand attachment, facile 
transmembrane delivery [10], reduced degradation of therapeutic payload nucleic acids [4, 5, 11, 
15, 122, 123], and potentially controlled intracellular release [15]. Controlled release 
mechanisms of drugs from nanomaterial surfaces have included thermal, pH, chemical, and ionic 
strength stimuli based processes. The optical and photophysical properties of metal nanoparticles 
further provide unique prospects for photo-controlled release and characterization of delivery 
and release based on SPR-enhanced imaging signals. 
1.4.2.1 Silver Nanoparticles as Drug Delivery Vehicles 
 Silver has not traditionally been applied in NP-based drug delivery applications, where 
gold[10-12] and other materials[114] have been popular, likely due to difficultly of SNP 
synthesis, reduced stability when functionalized according to popular salt-aging techniques, and 
former concerns about silver toxicity. However, clinical use of SNPs as effective antimicrobial 
solutions in wound care, as well as recent in vivo studies providing positive safety assessments 
for systemic exposure, have encouraged biomedical research with SNPs. A 2008 animal study 
revealed minimal induction of secondary markers of liver damage even in the presence of 
chronic oral SNP doses greater than 300 mg/kg/day for 28 days[124]. Reported safety and lack 
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of side-effects for SNPs administered at „moderate‟ doses[125] may lend greater confidence in 
the suitability of SNPs for in vivo solutions studies that seek to lower the threshold of „effective‟ 
SNP doses by harnessing their large drug payload capabilities and electromagnetic field 
amplifying characteristics. Recent improvements in SNP biocompatibility via surface 
modification, as well as exceptional optical properties [21, 28], have also improved suitability of 
SNPs for drug delivery.  
The unique field enhancement properties of SNPs, where the light scattering cross section 
of a silver nanoparticle is ~10 times greater than that of a similarly sized gold nanoparticle[21], 
have led to increased interest in their use as sensors[126, 127], biological labels[21], and 
substrates for surface-enhanced absorption, fluorescence[128], and photochemistry[16, 129]. 
Additionally, SNPs offer higher extinction coefficients and blue-shifted plasmon resonant peaks 
over other metallic nanomaterials[21, 28], making them an appropriate alternative for photo-
controlled drug delivery applications and potential surface-enhanced photochemistry of caged 
compounds such as nitrobenzyl derivatives. 
The optical properties and biocompatibility of SNPs are well described in the prior art and 
importantly they have distinct plasmon-related absorption spectra with maxima at ~420nm [14, 
128, 130-132]. This difference is critical to determining the role of plasmons in photoconversion 
of the nitrophenylethyl (NPE) photocleavable linker incorporated into our microRNA (miRNA) 
–SNP complexes (abs. max ~365nm). Previous studies have described both thermal and non-
thermal components of plasmon mediated catalysis which can increase reaction rates by 2-3 
orders of magnitude [133, 134]. The non-thermal component is likely related to intense electrical 
fields in the oscillating surface plasmon region interacting with ions and molecules thus reducing 
the activation energy of reaction.[133, 135] Metal enhanced fluorescence has been described 
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with silver nanostructures, wherein a resonance state or coupled photon is shared between a 
photoactive molecule and the metal nanomaterial resulting in more efficient 
photoconversion.[136]  
In the case of the miRNA-SNP, these quantum mechanical surface plasmon events could 
result in significantly lower required photon flux for cleavage and red-shifting the activation 
spectra, providing better tissue penetration and reduced photo-damage by transiting photons. Our 
SNP platform for antisense drug delivery and spatiotemporal release takes advantage of silver‟s 
unique photophysical properties for fluorescence confirmation of surface functionalization, cell 
uptake, and activation via nitrophenylethyl (NPE) nucleic acid linker photocleavage. 
1.4.2.2 Cytotoxicity Pathways of Silver Nanoparticles  
 In order for silver nanoparticles to be used in therapeutic delivery applications, the effects 
of SNPs on cell health must be studied, and shown to have no adverse affects at therapeutically 
applicable concentrations. Recently, studies on the use of SNPs in therapeutic applications, for 
example drug delivery, have met with concerns about the toxicity and negative effects of silver 
nanomaterials. 
Concerns of the impact of silver nanoparticles on cell health include decrease of 
mitochondrial function and induction of apoptosis, the mitochondria being a sensitive target of 
cytotoxicity of SNPs[137]. While the mechanisms of silver nanoparticle toxicity are not well 
characterized, they may involve surface binding (depletion) of thiol-containing proteins, 
including glutathione and key component enzymes of the cell‟s antioxidant defense mechanism, 
which leads to increased reactive oxygen species (ROS) generation, oxidative damage[137], and 
apoptosis, a complex programmed cell death pathway (Figure 1-3).  
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Particle surface electrostatic interactions with charged biomolecules might also attribute 
to the toxic properties often observed for „naked‟ silver nanoparticles at high 
concentrations[138]. Recent studies have also shown that primary cells have much higher SNP 
tolerance than concentrations often used for antimicrobial effectiveness[139]. Mechanism to 
improve the biocompatibility include functionalizing the metal nanoparticles with 
poly(ethylene)glycol (PEG) groups, lipids, polymers and small peptides.  
The surface modification of silver nanoparticles with thiol-modified biomolecules has 
been shown to improve silver biocompatibility and intracellular uptake[138]. The phospholipid-
protected silver nanoparticles were delivered into 3T3 fibroblast cells and platelet cells with 
minimal toxic effects.  
1.5 Metal Nanoparticle with Biomolecules 
 Recently the advancements in the field of functionalizing the metal nanoparticles, notable 
noble metals, with various organic compounds, including proteins, nucleic acids, long-chain 
hydrocarbons have gained increasing importance in the nanomedicine. These nano-hybrids 
incorporate the bioactive properties (catalytic functions, recognition and binding properties) of 
macromolecules with the unique optical and photochemical properties of noble metal 
nanoparticles[2]. This increasing importance stems from the ease of noble metal nanoparticle 
functionalization with biomolecules. The functionalizing chemistries can be broadly classified 
under electrostatic interactions as well as covalent binding [2]. Metal nanoparticles that are 
synthesized by salt reduction are in most cases stabilized by anionic ligands such as carboxylic 
acid derivatives[2], which give the metal particles a net negative surface to stabilize the particles 
and prevent particle-particle interactions (aggregation). This negative charge allows the 
positively charged ligands/functional groups (positively charged amino acid side chains of 
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proteins) to interact with the metal surfaces through electrostatic interactions [2]. On the other 
hand, the metal nanoparticles can also be functionalized with ligands and biomolecules by 
covalent coupling. Primarily, the binding of thiols to the metal surface (via covalent sulfur-metal 
bond), is a predominant method of nanoparticle functionalization[2]. Amine and carbonyl 
functional groups may also interact with the metal surface[140] and serve to tether biomolecules 
to the nanoparticle surface using standard conjugation chemistries.    
1.5.1 Silver Nanoparticles with Nucleic Acids 
 Nucleic acid-nanoparticle hybrids have been used for a variety of applications, including 
DNA detection based on LSPR absorbance changes[6, 126], particle assembly based on 
hybridization[9, 20, 22, 23], DNA intracellular delivery[3, 4, 10, 14, 114], and gene therapy[11, 
12]. Nucleic acids are typically immobilized on metal nanoparticles via covalent coupling (thiol 
end-modified nucleic acids). The nucleotide bases of single-stranded DNA (ssDNA) are also 
available for binding to the metal surface via amine and carbonyl functional groups[140, 141].  
Metal-biomolecule complexes are assembled by single molecule monolayers, or mixed 
monolayers (assembling a monolayer of one type of biomolecule and backfilling with another), 
on the nanoparticle surface via functional groups which interact with metal, such as thiols, 
amines, carbonyls, etc[142]. For thiol linkage of nucleic acids on metal surfaces to overpower 
other base interactions, techniques must be employed to create an environment where sulfur-
metal bonds are favored over other interactions. One of the method include custom-modifying 
the nucleic acids with thiol functional groups. This can assist in assembling a tightly-packed 
monolayer of nucleic acid on a nanoparticle surface.  The nucleic acids also have reactive 
functional groups (significantly amines) which can associate with metal surfaces and assist in 
stabilizing SNP-nucleic acid conjugates in the early stages of functionalization[143] 
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Typically nanoparticle-nucleic acid conjugates must be slowly adjusted to physiological 
salt concentrations (≈ 150 mM), conditions which serve to minimize the electrostatic repulsion 
between individual oligonucleotides („screening effect‟)[144] that arises due to the negatively 
charged state of the phosphate backbone. This screening will enhance surface coverage[9, 143, 
145, 146], as well as create an environment at the particle surface most favorable to ligand 
attachment via thiol bonding vs. amine, carbonyl, or other functional group interactions. Thus the 
required level of salt (typically NaCl) must be added gradually, and a fine balance must be struck 
in order to maximize surface coverage as well as colloid stability. Nanoparticle size 
(curvature)[147], oligonucleotide length and sequence[140], presence of „linkers‟ or spacers 
molecules, presence of low levels of surfactant[146], and final salt concentration have all been 
found to affect surface coverage and stability of SNP-oligo conjugates.  
 
Figure 1.3. Different pathways that silver nanoparticles take to attack the cells.  
1.6 Photo-controlled Release 
Light-responsive systems are of great interest in the field of drug delivery and gene 
therapy, owing to the capability of external, spatiotemporal control over the delivery and 
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activation of therapeutics coupled with such systems. Light-responsive drug delivery systems are 
triggered by electromagnetic radiation, typically in the UV, visible, and near infrared (NIR) 
range[148]. These systems are based upon photosensitive compounds which can be incorporated 
into a drug delivery vehicle, or coupled to the drug itself („caging‟ compounds), and may switch 
to an active or inactive state upon electromagnetic irradiation within a specific frequency range. 
Caged compounds are powerful tools for spatiotemporal control over drug activity in living 
systems[149]. Photocleavable groups have been used to cage, or inactivate, various 
biomolecules, including nucleotides, proteins, and nucleic acids[149-151], for the purpose of 
controlled, on-site photo-activation. Uncaging via light irradiation allows rapid, spatially and 
temporally defined release of a biomolecule at intended tissues or even within a specific 
intracellular compartment[149].  
1.6.1 Photocleavage Reaction Scheme 
 Photolabile ligands have been reviewed [152] giving a wide selection of available  
compound most for a specific caging application. An ideal caging compound should possess high 
extinction coefficient and quantum yield properties at wavelengths which are not detrimental to 
biological systems. The quantum yield ( ) of a photochemical reaction is defined as the 
efficiency with which absorbed light (incident photons) produces photolysis while the 
absorptivity of a compound at a particular wavelength of incident light is quantified in the 





 The most widely used photocleavable compound, 2-nitrobenzyl derivatives[149], has 
been used in the caging of adenosine 5‟-triphosphate (ATP) by Kaplan et al[153], with a reported 
maximum quantum yield of 0.63. The phosphate esters form of 1-(2-nitrophenyl)ethyl have been 
used to cage nucleotides[154, 155] with a reported quantum yields  of 0.49-0.63. Commercially 
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available 1-(2-nitrophenyl)ethyl (NPE)-based photocleavable (PC) linker has been used for 
immobilization onto solid surfaces, purification, and characterization of nucleic acids[156]. This 
PC linker demonstrates high photocleavage efficiency under UV-irradiation (300-350nm)[157], 
and has been chosen as the photo-labile group herein for immobilization and release of 
oligonucleotides from a metal nanoparticle surface.  
Upon photo-irradiation, the phosphodiester bond between the photocleavable group and 
the phosphate is cleaved, resulting in the formation of a 5‟-monophosphate on the released 
moiety (oligonucleotide)[156]. The 1-(2-nitrophenyl)ethyl moiety is converted to a 2-
nitrosoacetophenone derivative[154, 156]. The general photochemical reaction scheme of an o-
nitrobenzyl compound is shown in Figure 4. 
Figure 1.4 - O-Nitrobenzyl photochemistry[152, 158] 
1.6.2 Light Sources 
Typical light sources for uncaging emit UV radiation to excite photolysis of 
photocleavable compounds. Flash lamps, lasers, transilluminators, and laser microscopes with 
UV emissions in the range of 300-360nm are often used for uncaging. Lasers with narrow 
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excitations lines or broad bandwidth light sources equipped with filters to select for desired UV-
range wavelengths are appropriate sources. The electronic properties of SNPs may offer the 
potential of uncaging at higher wavelengths (visible to IR) due to SPR-enhanced excitation[159], 
which is of interest due to increased tissue penetration of longer wavelength light, and decreased 
probability of damage to biological components caused by high frequency (ultraviolet) 
electromagnetic energy.       
1.7 Two Main Antisense Modes of Action 
The underlying concept of antisense technology is basic Watson-Crick base pairing[160] 
between a delivered nucleic-acid and its complementary target. The antisense oligonucleotide 
(either DNA/RNA or small interfering (siRNA) either affect the transcription or translation 
pathways through two main methods: 1) enzymatic degradation of target mRNAs via RNase H 
2) steric hindrance of translation, transcription, or splicing. The antisense technology results in 
the inhibition of a protein. The RNase H pathway has been a gold standard in antisense 
technology, due to the fact that the antisense oligonucleotides involved are left intact and 
functional following target mRNA degradation, and are thus able to effect the degradation of 
many target mRNAs[161]. Conversely, the main limitation of this RNAase H antisense pathway 
was the lifetime of the antisense oligonucleotide. Non-specific side effects of the therapeutic 
molecule as well as its intracellular localization may also limit the effectiveness of any particular 
antisense oligonucleotide once delivered to a cellular target.  
1.7.1 Antisense Oligonucleotides 
Antisense oligonucleotides are short nucleic acids (10-30 base pairs long)[162] which 
interact with complementary mRNAs to prevent production of a specific protein. This inhibition 
of protein product production at the transcription or translation level is the hallmark of antisense 
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technology. This is in sharp contrast to other therapeutic drug that works on preventing the 
function of protein. Antisense oligonucleotides prevent transcription or translation of substrate 
nucleic acids in a sequence-specific manner, and are often directed to the 5‟ initiation sequences 
or 5‟ UTRs (untranslated regions) when the mode of action is steric hindrance[119], or almost 
any available binding site on an mRNA when the mode of action is degradation. It is interesting 
to note that initiation sequences and UTRs are often available for binding due to the fact that 
these sites are generally accessible to proteins such as transcription factors and ribosomes[119].  
 A major problem with phosphodiester antisense oligonucleotides is their susceptibility to 
degradation in the physiological environment[163]. The half-life of phosphodiester oligos, i.e. 
the time before half the molecules are inactivated by degradation, is only on the order of minutes 
when suspended in serum, or blood plasma. Serum contains 3‟5‟ exonuclease proteins, which 
are the primary agents of degradation for traditional, i.e. phosphodiester, antisense oligos[164]. 
Endonuclease enzymes are also responsible, to a somewhat lesser extent, for oligonucleotide 
degradation in the intracellular environment. Therefore, these phosphodiester oligonucleotides 
have very limited use in antisense therapy in natural form without chemically modification listed, 
in Figure 1-5[160], to inhibit degradation in a physiological environments.  
Chemically modified oligonucleotides are now available with longer half-lives in serum 
and resist nuclease degradation within the intracellular development. Phosphorothioate oligos, 
which have a modified phosphate backbone wherein a sulfur replaces the non-bridging oxygen, 
have a half-life in serum on the order of hours[165]. Phosphorothioate oligos, which are among 
the most extensively studied and practically applied antisense oligonucleotides[166], prevent 
mRNA translation via the RNase H degradation pathway. The use of this pathway for 
degradation of target nucleic acids, as well as the enhanced stability of phosphorothioates, 
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creates the appeal of this particular antisense molecule. Other chemically altered 
oligonucleotides with modifications to the phosphate backbone, sugar moieties, or nucleotide 
bases [160, 166] have been employed to minimize degradation or off-target effects of antisense 
drugs while preserving their specific hybridization to target DNAs/RNAs. Most of these 
modifications[166] produce antisense molecules which function via steric inhibition of 
translation, splicing, or transcription of target nucleic acids.  Antisense RNAs have also been 
chemically modified, via replacement of the ribose sugar 2‟ oxygen with a 2‟ O-methyl  group or 
a 2‟-florine, to resist enzymatic degradation and thus to have longer functional lifetimes in 
physiological environments. 
The criteria of an „efficient‟ antisense oligonucleotide have been enumerated as 
follows[162]: sequence-specific target recognition, high affinity for target DNA or RNA 
substrates, resistance to nuclease activity, sufficient plasma half-life, minimal „off-target‟ or non-
sequence-specific effects, and in ideal cases activation of RNase H, which effects degradation of 
target RNAs.  Also, an important alternative to further chemical modifications is the discovery 
and synthesis of novel nanoparticulate carriers[119, 167] that will both protect and efficiently 
„shuttle‟ drugs such as antisense oligonucleotides into cells[165]. 
1.7.2 RNAi 
RNA interference, or RNAi, is an emerging technology which involves the delivery of 
double-stranded siRNAs (small interfering RNAs) which activate intrinsic pathways leading to 
the enzymatic degradation of targeted (complementary) mRNAs[163, 168]. These pathways 
traditionally involve the enzyme complexes known as DICER and RISC, the latter of which 
functions in the unwinding of small double-stranded RNAs and in the cleavage of 
complementary RNAs[162]. RNAi, which is mediated by ssRNAs or small dsRNAs delivered to 
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targeted cells, is related to endogenous microRNA pathways[162], which serve to naturally 
regulate gene expression in higher organisms including humans.  
 
Figure 1.5 - Chemically modified antisense oligonucleotides (Dias & Stein 2002)[160] 
1.8 Single vs Double Stranded RNA for Gene Delivery 
 
Although the role of duplex RNA is critical in the early stages of RNAi and PTGS 
technology, there are multiple reports of single-stranded RNA (ssRNA) initiating the mRNA 
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knockdown. Martinez et al [170] reported that although ssRNA were involved in the RISC 
complex gene knockdown system, they required 10-100 fold higher concentrations of ssRNA 
compared to dsRNA to achieve the same effects. The knockdown was optimal for ssRNA that 
were >17 nt and improved by the addition of a 5‟ phosphate. Similar results were reinforced by 
Schwarz et al [171] when they evaluated both miRNA and siRNA and demonstrated that ssRNA 
for let-7 and luciferase mRNA required 5‟ phosphate. ssRNA mediated knock down is dosage 
dependant and is ~8-fold less effective than the corresponding duplex. Another study found that 
ssRNA, for human blood clotting initiator tissue factor (TF), was effective as the dsRNA at 
higher (100-200 nM) concentration[172].  
More importantly, the core components of RISC have been shown to bind to ssRNAs. In 
vitro binding studies have shown that ssRNA have almost 70-100 fold higher affinity than 
dsRNA. Also, 21 nt long ssRNA with 5‟phosphate bind to the recombinant Dicer with 
preferential affinity [173, 174]. The ease of functionalizing SNPs with ssRNA and their affinity 
for RISC complexes allowed us to select ssRNA over dsRNA for gene knockdown and 
differentiation of hASCs. dsRNA may be more potent than ssRNA but present the difficulty of 
attaching photo-cleavable group of the strand.  
1.9 Stem Cells and Differentiation 
1.9.1 Development of Germ Layers 
After the initial three days of fertilization, through mitotic division, the zygote changes to 
a mast of cells which then changes to blastocyst comprised of an outer layer, trophoblast, and an 
inner layer, the inner cell mast (ICM). The blastocysts are filled with uterine fluid and undergo 
implantation. Initially the ICM has two layers; hypoblast and epiblast. The epiblast later forms a 
new layer called endoderm and after pushing out the hypoblast, it forms the next two layers, 
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mesoderm and ectoderm.[169] Every germ layer gives rise to progenitor cells which are then 
differentiated to terminally differentiated cells. Some examples of terminally differentiated cells 
include central nervous, head connective tissues and mammary glands from ectoderm layer, 
stomach, colon, liver, pancreas and bladder from endoderm and skeleton, heart, kidney and 
spleen from mesoderm (Figure 1-6). 
 
Figure 1.6 – Germ Layer development and their differentiation lineages[170]. 
1.9.2 Adult Stem Cells 
Highly regulated processes of cell proliferation, migration, differentiation, and 
maturation, multiple cell lineages result in adult organisms from the earliest cell type in the chain 
called stem cells. The human adult stem cells are self-renewing and are capable of differentiating 
into multiple cell lineages (often multipotential). Upon physiologic cell turnover, tissue damage
 
due to injury or againg, these cells are capable of maintaining, generating, and replacing
 
terminally differentiated cells within their own specific tissue.[171, 172]. Some examples of 
differentiated cells from their parent progenitor cells are listed in Figure 1-7. 
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Figure 1.7: Adult human stem cells and their primary direction of differentiation 
1.9.3 Mesenchymal Progenitor Cells 
The bone marrow not only contains hematopoietic stem cells, but also the stem cells that 
can be defined as mesenchymatic. Traditionally mesenchymal stem cells (MSC) are found in the 
bone marrow but mesenchymal progenitor cells have been derived from multiple sources such as 
bone marrow[173], skeletal muscle[174], cartilage[175], tendon[176], adipose[177] and vascular 
smooth muscle cells[178]. These multiple studies have reported and indentified that MSC are 
great for self-renewal while maintaining their multipotency. They have also shown to 
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differentiate into osteoblasts, adipocytes, and chondrocytes as well as myocytes and neurons 
(Figure 1.8) 
The mesoderm layer differentiates into hematopoietic and connective tissue and 
mesenchyme is one of the embryonic connective tissue. On the other hand, stromal cells are 
connective tissue cells that form the supportive structure in which the functional cells of the 
tissue reside. With recent advancements in the isolation of MSC from non marrow sources, a 
better alternate suggested name can be termed as Multipotent Stromal cells. Various beneficial 
aspects of mesenchymal stem cells (MSC) including their ease of isolation and culture, high ex 
vivo expansion potential and their multipotency draws great attraction in terms of clinical 
applications. 
 






1.9.4 Osteogenic Differentiation of MSCs 
Mesenchymal stem cells are multipotent and can either replicate as undifferentiated cells 
or differentiate into lineages including including bone, cartilage, fat, tendon, muscle, and marrow 
stroma. Researchers have demonstrated that MSCs are capable of differentiating into bone and 
cartilage when placed into an appropriate environment in vivo [180]. Currently, MSC derived 
from adipose tissue are differentiated towards osteogenic lineages using culture medium 
supplemented with L-ascorbic acid 2-phosphate (AsA2-P), dexamethasone (Dex) and beta-
glycerophosphate (beta-GP)[181] 
1.10 Therapeutic Approach  
The genetically inherited skeletal tissue defects were cured by “cell replacement 
therapy,” in which the host stem cells were replaced by healthy donor cells. Clinically the MCS 
based therapies can be implemented in three different ways; 1) tissue-engineering strategies in 
which MSCs are incorporated into 3-D synthetic and biocompatible scaffolds, 2) replacement of 
mutant host cells with normal allogeneic donor cells and 3) MSCs provide growth factor that 
stimulate reparative events or to inhibit degenerative events. Herein, we will use a combination  
(miRNA) with MSCs derived from adipose tissue and incorporate them into biomaterial based 
scaffolds for in vivo regeneration of skeletal bone  
1.10.1 MicroRNA as Therapeutic Differentiation Agent 
Modulation of gene expression with microRNA (miRNA) is a promising technique for 
improving control of wound healing and tissue repair processes.[182] These short, non-coding 
RNA‟s are involved in post-transcriptional regulation pathways and in their mature form are 
found as single strands often associated with RNA silencing complexes.[183] MicroRNA‟s 
utilized in autologous, adipose derived mesenchymal stem cells (ASC) are an attractive 
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therapeutic modality for regenerative medicine. Directing the osteogenic and angiogenic 
differentiation of ASC is of particular interest in the design of therapies for critical size bone 
defects, spinal fusion and skeletal reconstruction. A summary of relevant osteogenic and 
angiogenic miRNA sequences can be found in Table 1. Four miRNAs, miR-26a, -148b, -27a and 
-489, have shown to regulate osteogenesis in mesenchymal stem cells (MSC). Of these 
compounds, miR-148b has been shown to induce de novo osteogenesis as indicated by increases 
in total alkaline phosphatase activity and early specific biomarker expression [184]. Several 
miRNAs, miR-126, 132, antagomiR-92a and let-7f, play a role in the regulation of angiogenesis 
and tumorigenesis (Table 1). While the expression of all six of these miRNA‟s modulate 
angiogenesis, none have demonstrated de novo angiogenic activity and only miR-126 has been 
explored in stem cells [185, 186]. 
Table 1.1: Relevant osteogenic miRNAs. miRNAs in bold will be evaluated. 
 
1.11 Clinical Relevance 
1.11.1 Bioscaffolds as Bone Cement Replacements 
Reducing or preventing the antibiotic resistance of microorganisms is one of the prime 
objectives of researchers in trauma surgery, to avoid infection and delayed wound healing. In 
 miRNA Relevant 
Targets 
Function Reference 
Osteogenic miR-26a hASC targets SMAD1 
transcription factor 
[187] 
 miR-125b Mouse MSC inhibits osteogenesis [188] 
 miR-148b hMSC de novo osteogenesis [184] 
 miR-27a  hMSC osteogenic [184] 
 miR-489  hMSC osteogenic [184] 
Adipogenic  miR-21 hMSC adipogenic (control) (49) 
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Chapter 2 we describe the synthesize of SNPs containing PLLA–PEG polymer scaffolds formed 
via a directional cryoprecipitation process, and the release of entrapped SNPs to onsite bacteria, 
while concomitantly supporting the growth of hASCs. Either of these individual functionalities 
has significant biomedical applications, whereas their combination has implications for surgery, 
where all are desired. The bioscaffolds in this formulation had lower ultimate compressive stress 
compared to other commercially available antibiotic-injected polymers, but the improved 
antimicrobial efficacy makes them a promising candidate to be used as bone cements for bone or 
soft tissue defects. 
1.11.2 Preventing Heterotopic Ossification in Bone Repair Therapies 
While the technology described in Chapters 3 and 4 has the potential to impact the 
treatment of many clinical conditions as it addresses the control of osteogenesis in stem cell 
mediated bone repair. Providing clinicians with improved spatial and temporal control of 
osteogenesis could address conditions such as heterotopic ossification (HO) which occurs 
frequently during surgical skeletal repair.  Heterotopic ossification, the mineralization of soft 
tissue also known as osseous metaplasia, is often associated with diffusible therapies such as 
bone morphogenic protein (BMP) used in repair of bone defects.[189] Maintenance of 
appropriate osteogenic concentrations with such short half-life diffusible factors at the site of 
bone repair requires high doses, resulting in a gradient of the bioactive compound in the 
surrounding soft tissue that can result in ectopic bone formation.[190-193] In cases where it is 
associated with joint or spinal tissue, the clinical complications of HO can be serious and costly 
for health care providers to correct.[194-199] Attempts to mediate the delivery of diffusible 
factors through localized injection and controlled release substrates have met with only limited 
success as control and localization of the dose remain problematic.[200-202]   
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Several other studies have examined gene delivery, using viral vectors or 
infected/transfected stem cells as an alternative to improve localization of osteogenic 
factors.[203-206] Direct viral vector delivery as a means of driving osteogenesis remains 
hampered by imprecise control over which cells are infected and levels of protein expression 
post infection. Injection of infected/transfected cells provides an effective means of localization 
but safety concerns related to levels of osteogenic protein expression and temporal control (i.e. 
when expression is turned on/off) limits enthusiasm for this technique.  
The miRNA-SNP system may serve as a potential solution to HO and related 
complications by providing greater temporal and spatial control over the activation of 
differentiation (Figure 1.9). While the miRNA-SNP conjugate or cells transfected with miRNA-
SNP may diffuse in vivo, they remain inert until activated with light, which can easily be 
pinpointed.  Additionally, since miRNA are short lived and only transiently modulate mRNA 
expression, it is expected that there is little chance of permanent activity once an activated cell 
has begun differentiation. The miRNA associated with inactivated conjugate are expected to 
degrade slowly intracellularly or in the intercellular space through enzymatic action or 
hydrolysis.  
This represents a paradigm shift from current methods of delivering osteogenic 
compounds such as diffusible BMP or gene delivery for BMP where there is little spatial or 
temporal control of expression respectively. The miRNA-SNP platform addresses both of these 
issues as: 1) miRNA payload can be activated with focused laser precision allowing activity only 
in the area of the bone defect, and 2) because miRNA are labile, activity is transient resulting in 
pathway regulation only in the critical early stages of cell differentiation. Additionally, as the 
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miRNA will only be transfected efficiently when bound to the particle, miRNA from conjugate 
activated in the intercellular space will have little impact on surrounding tissue. 
 
Figure 1.9. Overview of potential clinical implementation of Light Activated, miRNA Delivery 
system.  Injection of LAMD near critical bone defects, (or in seeded scaffolds,) followed by 
targeted photoactivation induces differentiation at select sites, with minimal side effects such as 
heterotopic ossification (HO). 
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2.1 Project Summary 
Nationally, nearly 1.5 million patients in U.S. suffer from ailments requiring bone grafts, 
hip and other joint replacements. Infections following internal fixation in orthopedic trauma can 
cause osteomyelitis in 22% to 66% of cases and if uncontrolled, the mortality rate can be as high 
as 2%. We characterize a procedure for synthesis of antimicrobial and biocompatible poly-L-
lactic acid (PLLA) and poly ethyleneglycol (PEG) bioscaffolds designed to degrade and absorb 
at a controlled rate. The bioscaffold architecture aims to provide a suitable substrate for the 
controlled release of silver nanoparticles (SNP) to reduce bacterial growth as well as aid the 
proliferation of human adipose derived stem cells (h-ASCs) for tissue engineering applications. 
The fabricated bioscaffolds were characterized with scanning transmission microscope (SEM) 
and it shows the addition of increasing concentrations of SNP results in formation of dendritic 
porous channels perpendicular to the axis of precipitation. The antimicrobial properties of these 
porous bioscaffolds were tested according to a modified ISO 22196 standard across varying 
concentrations of biomass mediated SNPs to determine an efficacious antimicrobial 
concentration. The bioscaffolds reduced the Staphylococcus aureus and Escherichia coli viable 
colony forming units by 98.85% and 99.9%, respectively, at an antimicrobial SNP concentration 
of 2000 ppm. Human ASC were seeded on bioscaffolds and in vitro cultured for 20 days to study 
the effect of SNP concentration on the viability of cells. SEM analysis and metabolic activity 
based fluorescent dye, alamarBlue®, demonstrated the growth of cells on the antimicrobial 
efficacious bioscaffolds. The biocompatibility of in vitro leached silver, quantified by 
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inductively coupled plasma optical emission spectroscopy (ICPOES), proved non-cytotoxic 
when tested against h-ASCs, evaluated by MTT assay.   
2.2 Introduction 
Infections following internal fixation in orthopedic trauma can cause significant setbacks 
to healing and have devastating long-term consequences. Traumatic injuries can involve 
significant soft tissue defects with exposed fractures in which there is a 22% to 66% rate of 
osteomyelitis, respectively, in civilian and military populations [1, 2]. Treatment for significant 
bony or soft tissue injuries usually require temporary stabilization (within 6 hr), prophylactic 
antibiotic therapy, irrigation/debridement, and subsequent definitive stabilization[2]. If 
uncontrolled, the mortality rates from osteomyelitis can be as high as 2 % [3]. Antibiotic-loaded 
bone cements, titanium cages, induced membranes, bone transport [4-6] have also been explored 
as prophylactic and therapeutic treatments for filling bone defects and treating osteomyelitis but 
their use has had limited clinical success. Despite these early and aggressive efforts, many 
patients (1-2%), predominantly young men with a median age of 24.5 and no co-morbidities, 
develop chronic osteomyelitis [7].  These patients would potentially benefit from engineered 
tissue repair solutions which reduce infection rates while improving regeneration of native tissue  
Synthetic scaffolds are being increasingly explored as a potential therapeutic modality to 
address limitations of autologus tissue grafting and alloplastic tissue repair. These constructs are 
designed to deliver bioactive materials such as drugs, cells, genes, peptides and/or proteins 
concomitantly with a degradable scaffold. The materials and porous architecture common in 
most scaffold designs perform a critical function in tissue regeneration by maintaining tissue 
volume, providing temporary mechanical stability, and delivering bioactive compounds [8-13].  
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A variety of “natural” (occurring in nature) and synthetic materials have been identified 
or developed which broadly meet the criteria to be considered bioresorbable or bioerodible and 
thus serve as good candidates for scaffold synthesis. Some of the broad categories include 
aliphatic esters, chitosan, aliginates, polyhydroxy acids and poly(tyrosine-carbonates) [14]. Of 
these compounds the material and chemical properties of aliphatic esters such as poly-L-lactic 
acid (PLLA) and poly-L-glycolic acid (PLGA) make them of interest for many indwelling 
applications including wound care and orthopedic device applications.  The in vivo degradation 
processes of these compounds have been well described and while there are some reports of the 
onset of late stage inflammation, these have been attributed to high molecular weight particles 
released from highly crystalline substrates [15, 16].  Most studies have found the implants with 
PLLA, PLGA or copolymers to result in very few rejection-related complications [17, 18].    
 Nanocomposite compounds provide a novel and flexible platform for incorporating 
drugs and other bioactive components into scaffolds. The large surface area and higher reactivity 
of nanoparticles when compared to bulk solids allow the particles to exhibit extraordinary 
chemical, physical and biological properties while the fundamentally small size minimizes the 
deleterious impacts traditionally associated with the formation of polymer composites containing 
a high volume fraction of solids [19]. Also, particles are means of achieving higher control of 
porosity, pore size, surface area and mechanical properties of scaffolds [20].  
 Herein we report on the development of a unidirectional cryoprecipitation process for 
forming monolithic, antimicrobial, multi-scalar nanocomposite scaffolds. This process, which 
makes use of a novel synthesis and purification methodology for silver nanoparticles (SNP) 
addresses the critical attributes of solubility, yield and purity, which to-date have prevented 
nanomaterials from widespread use in medical device applications. By varying the scaffold 
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composition and precipitation conditions, the fine micro- and nanostructure of this material can 
be controlled influencing the biocompatibility and reincorporation of materials into native bone 
structure. This manuscript describes the use of these two processes to develop proof of concept 
data supporting the use of antimicrobial nanocomposite scaffold composed of PLLA: 
polyethylene glycol and SNP to repair critical sized tissue defects.  Scaffold microstructure, 
viscoelastic mechanical properties, and its potential to serve as a substrate for hASC growth is 
demonstrated. The SNP concentrations and in vitro contact times required for the elimination of 
known titers of two model organisms, Staphylococcus aureus and Escherichia coli are evaluated. 
Additionally, the cytotoxicity of the released SNP and hydrolyzed product of PLLA-PEG 
bioscaffolds is tested against hASC to determine the suitability for use in stem cell based 
regenerative therapies. The values obtained provide baseline data to assess how SNP can best be 
implemented in nanocomposite bioscaffolds to create engineered, active antimicrobial tissue 
scaffolds.   
2.3  Materials and Methods 
2.3.1 Microbiology Test Organisms 
Escherichia coli (ATCC 29522) and Staphylococcus aureus (ATCC 6538) were 
inoculated and grown in sterile 15-ml centrifuge tubes (BD Falcon, Franklin Lakes, NJ) 
containing Nutrient Agar and BHI broth respectively and incubated at 37ºC. 
2.3.2 Cell Culture 
Human ASC were isolated according to the method described by Yu et al.[21] by the 
Stem Cell Biology Laboratory under a protocol reviewed and approved by the Institutional 
Review Board at Pennington Biomedical Research Center.  The ASC were isolated from 
lipoaspirates obtained from consenting patients undergoing elective plastic surgery. Human ASC 
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were maintained in 25-cm
2
 flasks (BD Falcon, Franklin Lakes, NJ) in stromal culture media at 
37 °C and 5% CO2 in a humidified atmosphere. Stromal culture media is composed of  
DMEM/Ham‟s F- 12 (1:1), 2.5 mm L-glutamine, 15mm HEPES supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% Antibiotic Solution (100X with penicillin, streptomycin, 
fungizone) until 80-90% confluent. The third passage (P3) cells were used in the extraction and 
metabolism studies. 
2.3.3 Biomass Mediated SNP Synthesis and Characterization 
The hydroxypropyl cellulose (HPC) stabilized SNP were synthesized by reducing silver 
nitrate with formaldehyde and characterized by transmission electron microscopy (TEM) and 
UV-Vis spectroscopy as previously published [22] 
2.3.4 Synthesis of Nanocomposite Scaffolds 
PLLA and PEG (3.5% wt each) were co-dissolved in dehydrated 1, 4-dioxane, Sigma 
Aldrich, at 50
o
C until transparent. Then 280 ul of deionized water (DI) water containing varying 
concentrations of colloidal SNP were mixed into the PLLA/PEG (Mw= 150,000 and 2200 
respectively) solution. After cooling to room temperature (RT), the solution was poured into a 
closed 4 cm long glass vial and the bioscaffolds were synthesized using a uni-directional freezing 
method similar to that previously described to form three–dimensional polymer structures by 
thermal precipitation [23]. Briefly, the vials are lowered into a liquid nitrogen bath at a constant 
rate of 2 cm/hr by a KDS230P syringe pump (KD Scientific, Holliston, MA). The insulated 
liquid nitrogen bath was designed with three orifices, each only slightly larger than the glass vial, 
milled into the insulted lid through which the glass vials were lowered. This process minimized 
evaporation of the liquid nitrogen and allowed the freezing liquid nitrogen vapor to access only 
the portion of the vial that had transited the orifice.   The vial caps were closed to prevent 
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absorption of moisture. After freezing the samples completely for two hours, the solidified 
PLLA:PEG sample was freeze-dried in Labconco FreeZone Plus (Kansas City, MO) at -85
o
C for 
4 days.  
2.3.5 Characterization of Bioscaffolds 
The solidified 2 cm long monolithic porous bioscaffolds were characterized with Joel 
JSM-6610LV (JEOL USA, Inc., Peabody, MA) scanning electron microscope (SEM) at 10 kV 
and inductively coupled plasma optical emission spectrometry (ICP-OES).   
The middle section of the bioscaffold was cut with a sharp razor blade both parallel and 
perpendicular to the direction of freezing to get hemi-cylindrical shaped samples. These samples 
were mounted on aluminum stubs with either Tubecote or colloidal graphite and sputter coated 
with platinum in Edwards S-150 sputter coater (Edwards High Vacuum Co. International, 
Wilmington, Massachusetts, USA).  
The amount of silver in the bioscaffolds was quantified by ICO-OES after digesting the 
contents with nitric acid.  The acidified solution was transferred to weighed ICP vials, agitated 
for 2.5 hrs and diluted to a final volume of 10 ml with acidified water. The final vials are 
weighed and the diluted samples were run on Varian Vista MPX (Palo Alto, CA). A no-SNP 
containing control sample was also compared. 
2.3.6 Antimicrobial Activity 
Quantitative antimicrobial testing with S.aureus and E. coli were conducted according to 
a modified ISO 22196 test methods which has a detection limit of 30-300 bacterial colonies. 
Briefly, 300 ul of the inoculated bacterial cultures were exposed to three cylindrical sections 
(d=12 mm and h= 1mm), cut from the middle section of the bioscaffold, containing varying 
concentration of SNP for 24 hrs.  The bioscaffolds were then washed with PBS to extract 
 65 
S.aureus and E. coli and plated on  Mannitol Salt Agar and MacConkey agar plates (BD Falcon, 
Franklin Lakes, NJ) respectively. A bioscaffold without SNP was also included in the dilution 
ladder as a control for each test organism to measure the efficacy of the coatings. The percentage 
reduction and colony forming unit (CFU) values were calculated similar to previously published 
work [22].  
2.3.7 Bioscaffold Rheology 
 Compression analysis on the SNP-bioscaffolds was conducted using a 1kN load cell of 
Instron
TM
 5582. Three cylindrical sections, 15 mm in height, of each concentration were 
compressed at a rate of 5mm/min until 90% strain was achieved. Stress-stain curves were plotted 
using the data collected from the BlueHill2 software (Instron, Norwood, MA). 
2.3.8 In vitro Release of Silver from Bioscaffolds 
SNP bioscaffolds, containing varying amount of SNP were exposed to 5 ml of PBS 
solution each for 5 days (n=3) at RT. Daily, 1 ml PBS solution was collected from each sample, 
without replacement for ICP-OES analysis. Prior to injection the solutions were incubated with 1 
ml nitric acid, transferred to weighed ICP vials, agitated for 2.5 hrs and diluted to a final volume 
of 10 ml with acidified water. The final vials are weighed and the diluted samples were run on 
Varian Vista MPX (Palo Alto, CA). A no-SNP containing control sample was also included.  
2.3.9 Cytotoxicity of Bioscaffold Extract on Human Adipose Stem Cells 
Three 9 mm
3
 cubes, cut from the middle of the bioscaffold, were placed in 2 ml Stromal 
culture media for 1, 5 and 20 days.  On the respective day, the media (extract) was collected and 
tested against hASC using TACS
TM
 MTT Assay (Trevigen Inc, Gaithersburg, MD).  A 100 ul 
cell solution (1.5x10
5
 cell/ml) was added to each well of a 96-well plate (BD Falcon, Franklin 
Lakes, NJ) for 24 hrs. The media was then exchanged with 100 ul of the extract and incubated 
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with the adhered cells for 24 hrs. On the following day, 15 ul of the MTT Reagent was added to 
each well for 3 hrs followed by the addition of MTT Detergent for 3 hrs. The absorbance was 
measured with a Wallac VICTOR
2
  V 1420-040 Multilabel Counter (PerkinElmer, Boston, MA) 
at 590 nm. 
2.3.10 Growth of hASC on Bioscaffolds 
 The hASCs were grown on bioscaffolds to study the cytotoxicity of the SNPs and 
released silver ions when in direct contact with cells. The 1 mm thick bioscaffold discs, cut from 
4 cm long bioscaffolds, were placed inside Plasma Cleaner 32PDC-23G (Harrick Plasma, Ithaca, 
NY) chamber and the internal pressure was lowered to 200 mTorr. The bioscaffolds were plasma 
treated for 10 sec to reduce the water contact angle for more facile hASC loading.  This process 
does not impact the bulk properties of the bioscaffolds. The bioscaffolds were then incubated 
with 1 ml cell solution (6x10
4
 cell/ml) in a 12-well plate (BD Falcon, Franklin Lakes, NJ) for 1, 
5 and 20 days. The growth of hASC was qualitatively and quantitatively analyzed with SEM and 
a metabolic activity indicator, alamarBlue® (Invitrogen Carlsbad, CA) respectively.  
To measure of metabolic activity, tissue cultured wells with no discs were seeded with an 
identical amount of cells as a positive control while wells with discs but no cells were employed 
as a negative control. On the respective days, the seeded discs were removed from the wells,  
washed with 1 ml of PBS and transferred to a fresh 12-well plate (to avoid the possibility of 
measuring cells seeded on to the initial well bottom during the seeding process).  A 0.5 ml 
portion of the 10% (v/v) alamarBlue® in stromal media was added to each disc, positive and 
negative control wells for 4 hrs. Then 100 μl sample of the mixture was removed and the 
fluorescence (λex =530 nm and λem =620 nm) was measured in a 96-well plate (BD Biosciences) 
using a Wallac VICTOR
2
 V 1420-040 Multilabel Counter. 
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 The discs seeded with hASC and cultured for 20 days were analyzed by SEM. The discs 
were removed from the cell media and fixed with 10% formaldehyde (Mallinckrodt Baker, NJ), 
10% glutaraldehyde (EM Science, PA) and 80% D-PBS for 15 mins. They were then rinsed in 
PBS to remove any residual fixing solution and placed in clean 60 mm glass petri dishes 
containing 0.25% solution of OsO4 in PBS for 30 mins at room temperature. The discs were 
washed with DI water and dehydrated with 50%, 70% and 100% ethanol for 15 mins each. 
2.4 Results and Discussions 
2.4.1 Characterization of Monolith Bioscaffolds 
SEM micrographs of a PLLA/PEG 50:50 blend after unidirectional freezing and freeze-
drying are shown in Figure 2.1. This cross-sectional view of the sample parallel to the direction 
of freezing (y-axis) provides an image of the honeycomb monolith structure, having 20 um inner 
diameter microtubes aligned along the freezing axis in the no SNP control (Fig. 2.1A). The 
uniform porosity of the bioscaffold was disturbed and the interconnected void space appeared 
more dendritic in structure with the addition of SNPs. The pores are oriented in the y-axis 
(Figure 2.1A) and with increasing concentration of SNPs (100 ppb – 200 ppm) the pores lose 
alignment along the y-axis and branch out in the y-x plane (Fig. 2.1 (B)-(I)).  It is hypothesized 
that the inclusion of SNP reduces the long-range crystallinity of the freezing solvent and prevents 
the formation of large continuous solvent crystals reducing the orientation of the scaffold and 
resulting in more dendritic pores. The size of the pore is ideal for the growth of cells and holds 
promise for bioscaffolds to be used in regenerative therapies [24]. 
ICP-OES quantified the amount of Ag+ ions present in the bioscaffolds with varying 
concentration of SNP (Fig. 2.1G). The amount of SNP in the bioscaffolds does not correspond to 
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its theoretical values and this can be hypothesized as due to losses during freeze drying and nitric 
acid digestion processes.  
2.4.2 Antimicrobial Activity of SNP in Bioscafffolds  
The bioscaffold nanocomposite compounds were challenged with two microorganisms 
E.coli and S.aureus. These strains were chosen as they are the two most commonly occurring 
strains of bacteria in Healthcare Acquired Infections (HAI) and have demonstrated resistance to 
several antibiotics including amoxicillin and methicillin respectively [25].  A bioscaffold without 
SNP was also included in the dilution ladder as a control for each test organism to measure the 
antimicrobial activity of the bioscaffold polymers. 
The percentage bacterial reduction across varying SNP concentration for S.aureus and 
E.coli on the monolithic bioscaffold is presented in Fig. 2.2. At every SNP concentration the 
S.aureus is more viable compared that of E.coli.  The thick peptidoglycan layer of S.aureus is 
believed to be interacting with the silver ions reducing the cytotoxic activity compared to E.coli. 
The results are similar to chloramphenicol (Cm) doped PLGA nanofibers where the percentage 
of inhibition were also larger for E.coli compared to S.aureus [26].  
  At 2000 ppm SNP, the CFU/ml decreased from 1.01 x 10
9 
to 4.20 x 10
6 





for E.coli and S.aureus respectively. These reductions correspond to a 3 log 
reduction (99.9%) reduction for E.coli and 98.85% reduction for S.aureus. There is a clear shift 
in the antimicrobial efficacy as the concentration is increased from 1 ppm to 700 ppm. The 
average percentage reduction changed from 38.6% to 80.38% and 28% to 86.11% (p < 0.05) for 
E.coli and S.aureus (Fig. 2.2 (A and B)). These results are improvements compared to recent 




Figure 2.1. SEM images of PLLA/PEG 50:50 blend co-polymer monolith bioscaffolds 
containing varying amounts of SNP (A) No SNP, (B) 100 ppb, (C) 1 ppm, (D) 700 ppm, (E) 800 
ppm, (F) 900 ppm, (G) 1000 ppm, (H) 1500 ppm and (I) 2000 ppm. (J) The amount of SNP in 
the bioscaffolds is quantified by ICPOES. The scale bar of SEM images are 200um. 
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Figure 2.2. Percent reduction of (A) E .coli and (B) S.aureus when exposed to varying 
concentrations of SNP (n=3).  
 
 
2.4.3 Mechanical Properties of Bioscaffold  
 The deformation of SNP-bioscaffolds when compressed in the direction of freezing 
follows a classical compressive stress–strain curve of samples with porous structures with 
distinct elastic and plastic regions. The compressive stress–strain curves of porous polymer 
scaffolds have three main characteristics: (a) linear elastic region at small strain (b) followed by 
a plateau region at larger stain and (c) a densified region with a very large increase in strain [29]. 
The rapid increase of the stress in the densified section occurred due to the collapse of the pore-
walls of the scaffolds [30]. The elastic-plastic flexion of bioscaffold occurs at ~10% strain and 
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the stress in the plastic (densified) region exponentially increases around 60% strain. The 
compressive modulus (Eelastic), compressive stress at 10% strain (σ10) which is a common 
indicator for the compressive properties of porous scaffolds are listed in Table 2.1 along with the 
ultimate compressive stress and average tangent modulus from 60-90% strain. The ultimate 
compressive stress decreases from 64.5 ± 26.5 kPa for no SNP control to 39.9 ± 1.4 kPa at 90% 
strain for 2000 ppm (Fig. 2.3). By increasing the amount of SNP, the ultimate stress of 
bioscaffolds decreases, which can be explained to the lack of any covalent linkage of SNP to the 
polymer. The SNPs are not used as reinforcing materials but as an antimicrobial agent to treat 
peri- and post-operative infection during wound healing.  Thus the tradeoff in mechanical 
properties versus antimicrobial functionality is seen with inclusion of SNP.   The Eelastic value of 
no SNP bioscaffold (3.47 ± 1.6 MPa) can be compared to the previously published value of 
5%wt PLLA scaffold fabricated with a similar technique [30]. 
 
Table 2.1: Ultimate compressive stress , Young‟s Modulus (Eelastic), compressive stress at 10% 
strain (σ10)  and average Tangent Modulus values of bioscaffolds. The vales are derived from the 





Figure 2.3. Stress-Strain graph of PLLA:PEG bioscafolds with varying concentrations of SNP. 
The average stress and strain values are plotted to compare the mechanical strengths of 
bioscaffolds by adding SNPs (n=3).  
 
2.4.4 In vitro Release of Silver from Bioscaffolds  
The antimicrobial and cytotoxic activity of the coatings is closely related to the rate of 
silver ion release from the bioscaffolds.  The amount of released silver ions with respect to PBS 
is quantified by ICP-OES and the results are shown in Fig. 2.4. For 1000 ppm and 900 ppm 
bioscaffolds the concentration of silver in PBS increased from 156 ± 26 ppb to 269 ± 8.9 ppb and 
82 ± 8.5 ppb to 190 ± 6 ppb respectively over the period of 5 days. The same trend was followed 
by a 700 ppm bioscaffold where the concentration increased from 114 ± 55 ppb to 143 ± 7 ppb 
while the concentration of silver ion released by the remaining bioscaffolds with lower silver 
concentration was nominal. The daily increment in the total amount of SNP released from No 
SNP, 900 ppm and 1000 ppm bioscaffold is statistically significant (p < 0.05; one sample t-test). 
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These results offer explanation to the bacterial reduction shown in Figure 2.2 (A) and (B) as 
silver ions released from the bioscaffolds act as an effective antimicrobial agent against E.coli 
and S.aureus. When compared to silver zeolites and silver containing bioglass containing 
scaffolds, the silver ions from the SNP in this formulation are more bio-available resulting in 
greater antimicrobial activity with lower concentrations of total silver.  
 
Figure 2.4. Silver release from the PLLA:PEG bioscaffolds over a period of 5 days as measured 
by ICP-OES. The average concentration of SNP from each bioscaffold is graphed above with 
bars representing the range of measured values. § and **The daily increment in the amount of 
SNP released from No SNP and 1000 ppm bioscaffolds respectively is statistically significant 
over a period of 5 days (p< 0.05; one sample t-test).  
 
2.4.5 Cytotoxicity of Extracted Materials 
 The extract containing the released SNPs and the hydrolyzed products of PLLA were 
non-cytototoxic to hASC as evidenced by MTT results (Fig. 2.5). The absorbance of the stromal 
media is subtracted from each value as background for MTT analysis.  The absorbance trends 
over 1, 5 and 20 days increase significantly over time for every sample (p < 0.05; one sample t-
 74 
test) indicating cell growth on all bioscaffolds and that the released products are below the 
cytotoxic thresholds for hASC. Also, the absorbance value of every bioscaffold is not 
statistically significant (p > 0.05; two-way ANOVA with Bonferroni post tests) from its 
respective no SNP control sample indicating that the growth of hASCs is comparatively 
maintained for that time point on the scaffold. With 2000 ppm bioscaffolds maintaining a 
comparable absorbance reading to no SNP sample, the results indicate that hydrolysis products 
of PLLA and the released SNP and ionic silver are largely non-cytotoxic to hASC over a range 
of therapeutically relevant concentrations.  
 
Figure 2.5. MTT absorbance measuring the viability of hASC when exposed to the media extract 
collected at 1, 5 and 20 days after initial cell seeding (n=3). The viability of hASCs from 
bioscaffold of every SNP concentration is not statistically insignificant difference from 
respective No SNP control samples (p > 0.05; two-way ANOVA with Bonferroni post tests). § 
The growth of hASC cell control is statistically significant difference over 20 days (p< 0.05; one 
sample t-test), *** The growth of hASC on 2000 ppm bioscaffold is statistically significant 
difference over 20 days (p< 0.05; one sample t-test).  
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2.4.6 Growth of hASC on Bioscaffolds 
The growth of hASC was supported by PLLA:PEG SNP-bioscaffolds over a period of 20 
days after initial seeding. The varying amount of SNP was not cytotoxic to hASC as growth of 
cells continued throughout the period of the experiment. The results were confirmed by 
alamarBlue® fluorescence and SEM images shown in Figure 2.6. SEM images of low (100 ppb 
and 1 ppm) and high (1000 ppm -2000 ppm) concentrations of SNP containing discs had extra 
cellular matrix on their surface 20 days after initial seeding, as seen in Figure 2.6 (A) - (F). This 
proves that the amount of SNP in the discs is non-cytotoxic to cells at all concentrations. These 
visual results were reinforced by the fluorescence data shown in Figure 2.6 (G). The fluorescence 
values were increased from day 5 to 20 days across all the concentrations of SNP (p < 0.05; one 
sample t-test) indicating the increment in the metabolic activity of the cells on the surface 
modified bioscaffold discs. Similar plasma treatments of scaffolds have also resulted in enhanced 
growth of stem cells [31]. The hASCs are maintained at every SNP doped bioscaffolds shown by 
statistically significant fluorescence value (p > 0.05; two-way ANOVA with Bonferroni post 
tests) compared to its respective cell only control sample. The inclusion of SNPs at these 
concentrations does not appear to have any adverse effects on the growth as shown by these 
results. These data also agree with similar reports where PLLA scaffolds were used to promote 
and aid the growth of stem cells [32, 33]. In summary, the 2000 ppm SNP-bioscaffolds achieved 
99.9% and 98.85% bacterial reduction after 24 hrs of bacterial inoculation while supporting 
growth of hASC for 20 days. The in vitro released silver ions at the levels tested were non 





Figure 2.6. SEM images of hASC, 20 days after initial seeding, on bioscaffolds with varying 
concentrations of SNP; (A) No SNP, (B) 100 ppb, (C) 1 ppm , (D) 1000 ppm, (E) 1500 ppm and 
(F) 2000 ppm. The fluorescence measurement of alamarBlue are plotted in graph (G). * 
statistically significant difference compared to cells only at day 20 (p < 0.01; two-way ANOVA 
with Bonferroni post tests). # statistically insignificant difference compared to cells only at day 5. 
§ § § The growth of hASC cell control is statistically significant difference over 20 days (p< 
0.05; one sample t-test), ¥¥ The growth of hASC on 2000 ppm bioscaffold is statistically 
significant difference over 20 days (p< 0.05; one sample t-test). 
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2.5 Conclusions 
Reducing or preventing antibiotic resistance of microorganisms is one of the prime 
objectives of researchers in trauma surgery to avoid infection and delayed wound healing. 
Herein, two main techniques have been discussed to synthesize SNP containing PLLA: PEG 
polymer scaffolds formed via a directional cryoprecipitation process, and the release of 
entrapped SNPs to onsite bacteria, while concomitantly supporting the growth of hASC.  Either 
of these individual functionalities has significant biomedical applications, whereas their 
combination has implications for surgery, where all are desired. The results demonstrate that the 
SNP were uniformly distributed in the scaffolds, leading to silver ion release that inhibited the 
proliferation of S.aureus and E.coli by 98.85% and 99.9% respectively for the 2000 ppm case. 
The bioscaffolds and its extract were non cytotoxic to hASC in vitro and supported the growth of 
cells for 20 days after intial seeding. The bioscaffolds in this formulation have lower ultimate 
compressive stress compared to other commercially available antibiotics injected polymers but 
the improved antimicrobial efficacy makes them a promising candidate to be used as fillers for 
bone or soft tissue defects.   
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Chapter 3. miR-148b-Nanoparticle Conjugates for Light Mediated 




3.1 Project Summary 
Delivery systems providing spatial and temporal control have the potential to improve 
outcomes in surgical reconstruction and regenerative medicine by precise modulation of wound 
healing and tissue repair processes. In this study we describe a synthesis and oligonucleotide 
functionalization process of silver nanoparticle complexes for photo-activated microRNA 
(miRNA) delivery. The activity of the PC-miR-148b-SNP construct is demonstrated by light 
mediated delivery of miR-148b mimic resulting in differentiation of human autologous adipose 
derived mesenchymal stromal/stem cells (hASCs) into a osteogenic linage. The conjugate, upon 
photoactivation, increases alkaline phosphatase (ALP) activity in the cell membrane and 
calcification (mineralization) of hASCs on day 7 and 14 respectively. Additionally, the 
expression of mRNA for the early, middle and late stage osteogenic markers; ALP, RunX2 and 
osteocalcin (OCN) respectively, were also significantly upregulated at day 7 and 28, respectively 
after photoactivation of PC-miR-148b-SNP and release of miR-148b mimics. Additionally, PC-
miR-148b-SNP conjugate is readily delivered to the intracellular compartment without the use of 
transfection vectors commonly required for free oligonucleotides. This technology demonstrates 
photo-controlled, spatial and temporal modulation of osteogenesis in hASCs. 
3.2 Introduction 
Modulation of gene expression with miRNA is a promising technique to improve control 
of wound healing and tissue repair processes.[1] These short, non-coding RNA‟s are involved in 
post-transcriptional regulation pathways and in their mature form are found as single strands 
often associated with RNA silencing complexes.[2] MicroRNAs with the potential to modulate 
                                                 
2
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differentiation and wound healing, utilized in conjunction with autologous, adipose derived 
mesenchymal stromal/stem cells (ASCs) are an attractive therapeutic modality for regenerative 
medicine. Directing the osteogenic differentiation of ASCs is of particular interest in the design 
of therapies for critical size bone defects, spinal fusion and skeletal reconstruction. In a previous 
study, by Schoolmeester et al., miR-148b  was shown to induce de novo increases in total ALP 
activity, an early biomarker of osteogenesis in bone marrow-derived mesenchymal stem cells.[3] 
Technology developments that provide spatial and temporal control of miRNA delivery and 
activity would improve the clinical relevance of miRNA therapies, but to date, this remains a 
challenge. Of particular interest is the development of delivery vehicles capable of activation by 
a non-invasive trigger such as light or ultrasound stimulation [4-6].  
Studies on metallic nanoparticles (NPs) have emphasized the benefits of using noble 
metal nanoparticles in delivery applications including ease of bulk synthesis, readily tunable 
morphology, large surface area-to-volume ratios and robust functionalization chemistries. [7]. 
Clinically, SNPs have been used as effective antimicrobial solutions in wound care. Recent in 
vivo studies have provided positive safety assessments for systemic exposure thus encouraging 
its used in biomedical research [8-11]. A 2008 animal study revealed minimal induction of 
secondary markers of liver damage even in the presence of chronic oral SNP doses greater than 
300 mg/kg/day for 28 days[12]. Reduced side-effects of administered SNPs at „moderate‟ 
doses[13] may lend greater confidence in the suitability of SNPs for in vivo biomedical solutions 
considering studies that seek to lower the threshold of „effective‟ SNP doses by harnessing their 
large drug payload capabilities and electromagnetic field amplifying characteristics. These 
advantageous properties have allowed NPs to be used in the delivery of various therapeutic 
agents including small molecules [14, 15], antisense oligonucleotides [16, 17], and siRNAs. [18-
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20] Additionally, metal nanoparticles fulfill the core requirements as drug delivery vehicles by 
offering high-density surface ligand attachment, facile transmembrane delivery [17], reduced 
degradation of therapeutic payload nucleic acids [18, 21-25], and potentially controlled 
intracellular release.[25]  
Several attempts have been made to release nucleic acids from surfaces (including 
nanoparticles) via thermal [5], pH [26], ionic strength, and chemical stimuli [27] but greater 
control of spatial selectivity can potentially be achieved with photo-activated delivery systems. 
Photocleavable groups, such as nitrophenylethyl (NPE), have been used to cage various 
biomolecules, including nucleotides, proteins, and nucleic acids [28-30] for in situ photo-
activation. Based on these previous studies it is expected that photo-activation via irradiation will 
allow rapid spatially and temporally defined release of a miRNA within a specific intracellular 
compartment.  
Silver nanoparticles (SNP) have unique optical properties including a localized surface 
plasmon field that is ~10 times greater to that of similarly sized gold nanoparticle.[31] These 
optical properties have increased interest in their use as sensors[32, 33], biological labels[31], 
substrates for surface-enhanced absorption, fluorescence[34], and photochemistry.[35, 36] SNP 
also offer higher extinction coefficients and blue-shifted plasmon resonant peaks compared to 
many other metallic nanomaterials[31, 37], taken together this indicates that SNPs may be an 
appropriate alternative for photo-controlled drug delivery using caged compounds such as 
nitrobenzyl derivatives.  
Herein we describe the synthesis, characterization and in vitro function of a light 
activated, miRNA delivery particle that may serve as a potential solution for the repair of critical 
sized skeletal defects by providing greater temporal and spatial control over stem cell 
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differentiation.  The light activated technology described in this study links a truncated single 
stranded microRNA148b mimic to silver nanoparticle surface via a photocleavable (PC) linker 
providing for the release and activation of miRNA from the particle by a discrete photo-trigger. 
The facile in-place exchange strategy for the synthesis of SNP based light activated miRNA 
delivery system is described and the resulting construct called PC-miR-148b-SNP is 
characterized by light scattering, electron microscopy, UV-Vis spectroscopy, optical emission 
spectroscopy and fluorometry.  The osteogenic differentiation of human adipose derived 
mesenchymal stromal/stem cells by miR-148b is demonstrated and further characterized in vitro. 
Uptake and intracellular trafficking of the PC-miR-148b-SNP construct is observed and photo-
triggered release of micro RNA is quantified.   Finally photo-triggered restoration of miRNA 
activity from the PC-miR-148b construct is demonstrated by light modulated hASCs osteogenic 
differentiation in vitro and compared to standard cationic transfection agents.  
3.3 Materials and Methods 
3.3.1. Materials 
HPC-SNPs were synthesized as described by Qureshi et al[9]. Silver surfaces were 
functionalized with custom thiol-modified oligonucleotides ordered from TriLink Bio 
Technologies (San Diego, CA). 2M Tris-NaCl buffer (pH 8.0) was made up from Biotechnology 
grade Tris (Amresco Inc, Solon, OH) and sodium chloride (Fischer Scientific, Pittsburgh, PA). 
Dithiothreitol (1M aqueous) and TRI Reagent were purchased from Sigma (St. Louis, MO).  
3.3.2 Cell Culture 
Liposuction aspirates from subcutaneous adipose tissue were obtained from three female (Age: 
20- 45 yrs and BMI= <30) subjects undergoing elective procedures. All tissues were obtained 
with informed consent under a clinical protocol reviewed and approved by the Institutional 
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Review Board at the Pennington Biomedical Research Center (#23040). Isolation of hASC was 
performed as described elsewhere [38]. Human ASCs were maintained in 25cm
2
 flasks (BD 
Falcon) in stromal culture medium (SM) at 37
o
C and 5% CO2 in a humidified atmosphere. SM is 
composed of Dulbecco‟s minimal essential medium (DMEM):Ham‟s F-12 (1:1), 2.5mm L-
glutamine, 15mm HEPES supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic 
solution (100x with penicillin, streptomycin, fungizone) until 80–90% confluent. Freshly isolated 
hASC were cyropreserved at Passage 0 abd thawed for subsequent use at Passage 2 for each 
individual donor used for all in vitro experiments. 
3.3.3 Osteoinductive Induction 
To evaluate the ability of miR-148b to modulate osteogenesis, approximately 1x10
5
 
hASCs were seeded in 48-well tissue culture plate (BD Falcon, Franklin Lakes, NJ). Cells were 
allowed to incubate for 24hr in SM at 37°C prior to PC-miR-148b-SNP construct treatment. 10 
ul of 70 ppm HPC-SNPs and 10 ul of PC-miR148b-SNP construct (227.2 ± 1.7 ppm SNP and 40 
nM PC-miR-148b) were added to cells for 16 hr before photo-release. For photo-release, the PC-
miR148b-SNP treated cells were photo-activated for 5 min at 365nm (52.4 J/cm
2
) by means of a 
GreenSpot system (American Ultraviolet, Lebanon, IN), which incorporates a 100–watt, 
pressurized mercury lamp with 5mm x 1000mm light guide, and produces a peak spectral output 
at 365nm (American Ultraviolet, Lebanon, IN). The lamp has a fluence of 206 mW/cm2 with the 
short bandpass (1.5mm thick, 2.4mm diameter SWP–2502U–400, Lambda Research Optics, CA) 
and IR filters (818–ST–UV detector, Newport Corporation, Irvine, CA) in place. The test groups 
included hASCs maintained in OM and cells transfected with single stranded 22 nt miR-148 by 
TurboFect (Table 1). The Control groups included hASCs maintained in SM, cells transfected 
with single stranded miSpike-21mer by TurboFect (universal control). The TurboFect 
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transfection was conducted according to manufacturer‟s protocol. Other controls include photo-
exposed hASCs and cells transfected with PC-miR148b mimic. The initial media was exchange 
was performed 48 hr post photo release (64 hr post treatment) and the cells were maintained for 
either 7, 14 or 21 days while exchanging media every 3 days. Table 1 shows the sequence of 
miRNAs used in this study and the placement of 2‟-O-methyl protection of nucleotides.  
3.3.4 Silver Nanoparticle Functionalization 
Silver nanoparticles were functionalized via a modified „salt-aging‟ technique. Custom 
thiol and photo-cleavable group-modified, 6-TAMRA-labeled oligonucleotides (PC-miR-148b) 
were mixed with HPC-SNP (70pM) at a oligo-to-particle stoichiometry of 5000:1, and left to 
incubate at 37°C under gentle rocking conditions to favor initial oligonucleotide. Following a 
24hr incubation period, a 48hr Tris-buffer based salt-aging process was commenced during 
which the SNP-oligo conjugate solution was first rapidly adjusted to 1% SDS and 25mM 
phosphate buffer, and subsequently slowly (1x 5ul aliquot additions of a 1M Tris-NaCl buffer 
per 24hrs) adjusted to 20mM NaCl and 10mM Tris buffer (pH 8.0) concentration. Functionalized 
nanoparticles were purified via centrifugation (3 x 7000 RPM) and resuspended in a modified 
buffer (1% SDS, 50mM Tris-NaCl) prior to experimental analysis.  
3.3.5 SNP and Conjugate Characterization 
For UV-Visible spectroscopic characterization, naked and PC-miR-148b functionalized 
SNPs were diluted to appropriate concentrations in DI water. Diluted samples were analyzed for 
absorption properties in a wavelength range scan (200-700nm). For TEM characterization, 5 ul 
of SNP solution and 5ul PC-miR-148b functionalized SNP) conjugate solution were pipetted on 
Carbon/Copper 20-30 nm grids (EMS, Hatfield, PA), air dried and visualized with JEOL 100CX.  
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The changes in electrical potential across the double layer were also measured with dynamic 
light scattering (DLS). 
3.3.6 PC-miR-148b Coverage Quantification  
PC-miR-148b coverage on functionalized SNP-conjugates was quantified via 
fluorescence-based measurements of particle-released oligonucleotide samples. Following PC-
miR-148b-SNP functionalization and purification, the oligonucleotide was cleaved from the 
SNPs via two methods; 1) 1% dithiothreitol (DTT) was added to SNP-conjugate solutions and 
allowed to shake at 37 °C for 10-15min and 2) 1ml of prepared PC-miR-148b-SNP conjugates 
were loaded in a demountable quartz cuvette chamber (5mm path length, 49-Q-5, Starna Cells 
Inc, Atascadero, CA) and irradiated at 365nm by means of a GreenSpot. After treating the 
samples with either DTT or 365nm radiation, the samples were centrifuged (1 x 7000 RPM). The 
supernatant (PC-miR-148b) was quantified via fluorimetry with Wallac VICTOR2 V 1420-040 
Multilabel Counter (Perkin-Elmer, Boston, MA, USA) at excitation/emission lines set at 
531/572nm. A standard curve depicting the fluorescence of varying concentration of PC-miR-
148b was plotted to calculate the amount of oligonucleotide on the particles. The silver content 
of HPC-SNPs pellet was quantified via inductively coupled plasma optical emission 
spectrometry (ICP-OES) (Varian, Palo Alto, CA, USA). Particle sizes estimated from TEM, in 
conjunction with silver content, were used to calculate total particle numbers according to the 
previously published method[39, 40].  
3.3.7 Histochemical Staining 
ALP histochemistry was performed on hASCs exposed to different treatments at day 7. 
The ALP up-regulation was qualitatively and quantitatively measured by Millipore kits, SCR 
004 and SCR 066 respectively according to manufacturer‟s instructions. Briefly, hASCs were 
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fixed with 4% formaldehyde in Dulbecco's Phosphate-Buffered Saline (DPBS) for 1-2 min and 
then rinsed DPBS. The cells are then stained with Fast Red Violet solution and Napthol AS-BI 
phosphate solution before imaging the cells with color camera mounted on Olympus cell TIRF 
illuminator light microscope. For quantitative measurement, 2x10
4 
cells were isolated from each 
sample and reacted with p-nitrophenylphosphate (p-NPP) substrate provided in the kit. The 
absorbance of p-nitrophenol was measured at 405 nm with Wallac VICTOR2 V 1420-040 
Multilabel Counter and normalized to number of hASCs, measured by PicoGreen (Life 
Technologies, Eugene, OR) at 7 days[41, 42].  
For Alizarin Red histochemistry, the cultured cells were stained on day 14 for assessing the 
mineralized matrix.  The media was removed, and the cell layers were rinsed with DPBS before 
staining with 2% Alizarin Red (2g/100mL DI water, pH adjusted to 4.1 by adding 10% 
ammonium hydroxide) for 10 min. The cells are then washed with DPBS six times before 
imaging on Olympus cell TIRF illuminator light microscope. To quantify the mineralization of 
hASCs with photoactivated PC-miR148b-SNP the cells were destained by the addition of 400 ml 
of 10% cetylpyridinium chloride monohydrate to each well followed by shaking for 10 min at 
room temperature. The calcium deposition expressed by the optical density of the aliquots was 
then measured at 540 nm with a plate reader and normalized to number of hASCs, measured by 
PicoGreen (Life Technologies, Eugene, OR) at 14 days [41, 42].  
3.3.8 Quantitative Real Time Polymerase Chain Reaction (Q-PCR) 
Total RNA was extracted from injected/transfected hASCs with Tri Reagent according to 
the manufacturer‟s instructions. The extracted RNA was then used to perform Q-PCR with 
iScript™ One-Step RT-PCR Kit with SYBR® Green using MiniOpticon™ Real-Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, CA). The sequences of PCR primers 
 89 
(forward and backward, 50 to 30) used to assess the osteogenic differentiation of hASCs with 
nanoparticles were as follows: ALPL, 5‟- AATATGCCCTGGAGCTTCAGAA -3‟ and 5‟- 
CCATCCCATCTCCCAGGAA -3‟; osteocalcin (OCN), 5‟- GCCCAGCGGTGCAGAGT -3‟ 
and 5‟- TAGCGCCTGGGTCTCTTCAC -3‟and Runx2; 5‟-
GCAAGGTTCAACGATCTGAGATT- 3‟ and 5‟- AGACGGTTATGGTCAAGGTGAAA- 3‟. 
Samples were normalized (ΔCt) against the house keeping gene 18SrRNA and -ΔΔCt value of 
ALPL, OCN and Runx2 in hASCs, relative to SM, was calculated using the ΔΔCt method[43]. 
3.3.9 In vitro Photo-release of PC-miR-148b 
Confocal microscopy was used to monitor in vitro photo-release of PC-mir-148b from the 
conjugate. hASCs were seeded in 1.0 Borosilicate cover glass Lab-Tek™ 4-well chambered 
slides (Thermo Fisher Scientific, Rochester, NY) and treated with PC-miR-148b-SNP conjugates 
as described in section 2.3. To calculate the co-localization coefficient and better visualize the 
intracellular distribution of PC-mir-148b-SNP and activated constructs, 100 ul of 227.2 ± 1.7 
ppm PC-miR-148b-SNP was injected to hASCs. Similarly cells were flashed for 5min at 365nm, 
4hr prior to imaging (20hr post PC-miR-148b-SNP conjugate delivery). All samples were 
resuspended in OPTI-MEM
®
 prior to imaging. The Leica TCS SP2 spectral confocal & 
multiphoton system used consists of a Leica DM IRE2 inverted microscope with a galvo-Z stage. 
Excitation lasers at 488 and 543nm were used in imaging experiments, concurrently with tuned 
emission wavelength windows. Reflectance mode images of SNPs (488/492 nm) and 6TAMRA 
labeled PC-miR-148b fluorescence (543nm/572 nm) were overlayed to visualize the co-
localization difference between the radiated and non-radiated samples. Images were analyzed 
using Leica Confocal Software (LCS) Lite (Leica Microsystems Heidelberg GmbH). 
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3.3.10 Osteocalcin ELISA  
To evaluate OCN levels in the hASCs treated with PC-miR-148-SNP (radiated and non-
radiated) along with other controls mentioned in section 2.3 for 14 or 28 days. The cell media of 
last four days for each sample was collected and tested for OCN secretion using a commercially 
available kit (Life Technologies, Grand Island, NY). The media was incubated with microplate 
coated with osteocalcin antibody before introducing anti-osteocalcin horseradish peroxidase 
(HRP) conjugate.  The plate was then washed, incubated with Chromogen 
(Tetramethylbenzidine) and stopping reagent respectively.  The product was measured at 450 
nm, and the amount of OCN was quantified with a standard curve and then normalized to 
number of hASCs measured by PicoGreen (Life Technoligies, Eugene, OR), at 14 and 28 days 
respectively [44]. 
3.3.11 Measuring Cytotoxicity of PC-miR148b-SNP with Flow Cytometry 
 A 1 ml cell hASCs solution (1x10
5
 cell/ml), was plated on 48 well tssue culture plates 
for 24 hrs before as mentioned in section 2.3. After the photoactivation the samples were 
maintined in the plates for 28 days while exchanging the media every 3-4 days.  For a necrotic 
control, hASCs were incubated for 4 hr in 75% ethanol.  After treatment, adhered hASCs were 
harvested by trypsinization (0.25% Trypsin), washed with 1 ml D-PBS, pooled together with the 
detached hASCs and centrifuged at 1800 rpm to obtain cell pellet. Cells were re-suspended in 1 
ml D-PBS and stained with 4 ul of 1.2 uM Sytox Red (Life Technologies, Eugene, OR) for 15 
mins in the dark, then centrifuged and fixed in 250 ul of 1% paraformaldehyde (PFA) solution in 
PBS for flow cytometric analysis of viability with a BD FACSCalibur cytometer (Franklin 
Lakes, NJ). For each sample, scatter and fluorescent data was collected for 30,000 cell events 
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using Cellquest pro (BD Biosciences, San Jose, CA) and former analyzed using WinMDI 2.8 
software (by Dr J. Trotter, Scripps Institute, La Jolla, CA). 
3.3.12 Statistical Analysis 
All results were expressed as mean ± % error.  Data was analyzed with one way t-test. For all 
comparisons, a p-value < 0.05 was considered significant. 
3.4 Results and Discussion 
3.4.1 miR-148b and miR-148b* Osteogenic Properties of Free Oligonucleotides  
 
In studies conducted by Schoolmeesters et al., the expression of miR-148b mimics were 
found to upregulate the activity of ALP in human, bone marrow derived MSC, de novo, without 
other osteogenic stimuli.[3] Initial experiments were conducted as part of this study to expand 
this work to hASCs and to include a late stage marker of differentiation, OCN, for a more 
thorough evaluation of miR-148b‟s osteogenic potential. Additionally, a dose response for the 
truncated miR-148b and miR-148b* mimic sequences was determined and the impact of strand 
hybridization on ALP and OCN expression was explored (Figures 3.1 and 3.2) using cationic 
transfection agents as a delivery vector. Post transfection ALP and Alizarin Red assays 
demonstrated upregulated ALP activity and greater Alizarin Red staining of hASCs transfected 
with miR-148b mimic compared to miR-148b* mimic (Figures 3.3 and 3.4). These results 
demonstrate that miR-148b  and miR-148b* sub-sequences are both capable of driving the 
expression of common osteogenic markers hASCs. 
Based on these results, a single stranded miR-148b mimic (Table 3.1) was selected for 
inclusion into the PC-miR-148b-SNP conjugates and used in all future experiments. Unlike 
mimics used by Schoolmeesters et al, the mimics in this study were single stranded to reduce the 
footprint and increase nucleic acid packing density on the particle. This has been shown to 
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reduce nuclease attack and oligo degradation in similar particle systems.[16, 45]  A target 
miRNA mimic concentration of ~400nM was chosen for all experimental and control samples, 
and delivered concentrations are based on total oligo present on the particle rather than on 
estimations of released miRNA mimic. After purification 40 nM of PC-miR-148b was recovered 
from the SNPs irradiation. 
 
 
Figure 3.1: Semi-quantitative gel analysis of RT products with respect to its respective 18s rRNA 
band for ALPL. (A) Represents the ALPL and their 18srRNA bands while (B) show the relative 
ALPL intensity of each sample compared to 18srRNA internal control. § indicates difference 
from respective controls (SM or OM) (p < 0.05; two-way ANOVA with Bonferroni post tests). 




Figure 3.2. Semi-quantitative gel analysis of RT products with respect to its respective 18s rRNA 
band for OCN. (A) Represents the OCN and their 18srRNA bands while (B) show the relative 
OCN intensity of each sample compared to 18srRNA internal control. § indicates difference 
from respective controls (SM or OM) (p < 0.05; two-way ANOVA with Bonferroni post tests). 




Figure 3.3: Alkaline Phosphatase (ALPL) up-regulation was qualitatively measured by Millipore 
kits, SCR 004 on hASCs transfected with (A) single-stranded miR-148b* in stromal media (SM), 
(B) hybridized miR-148b and miR-148b* in SM, (C) single-stranded miR-148b* in osteogenic 
media (OM) and (D) hybridized miR-148b and miR-148b* in OM. Magnification is 20x, and 




Figure 3.4: The mineralization of hASC treated with varying conditions was quantified by 
staining cells with Alizarin Red. The hASCs were transfected with (A) single-stranded miR-
148b* in stromal media (SM), (B) hybridized miR-148b and miR-148b* in SM, (C) single-
stranded miR-148b* in osteogenic media (OM) and (D) hybridized mir-148b and mir-148b* in 
OM. Magnification is 20x, and scale bar is 100um. 
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Table 3.1. Sequence of miRNA used in this study. The first three nucleotides of miSpike-21-mer, 






3.4.2 Functionalizing HPC-SNP with PC-miR-148b 
 
The photo-labile oligonucleotides for conjugation to SNPs surfaces were designed to 
optimize surface coverage, SNP-conjugate stability, and surface-enhancement of photochemical 
processes, including fluorescence detection and photolysis of the nitrophenylethyl (NPE) internal 
photocleavable linker (Figure 3.5A). Silver NPs were chosen as a platform as the optical 
properties and biocompatibility are well described in the literature; silver has distinct plasmon-
related absorption spectra with maxima at ~420nm, which overlaps with the maxima of the NPE 
linker (365nm).[34, 46-49] The hydroxypropyl cellulose stabilized silver nanoparticles (HPC-
SNPs) were prepared according to previously described methods and characterized via UV-Vis 
spectroscopy, TEM and DLS. [9]  
Upon attaching PC-miR148b to silver particles to form the PC-miR-148b-SNP conjugate, 
a slight red-shifting of the SNPs resonance peak is observed by ~5 nm to 418 nm, (Figure 3.5B). 
This perturbation of the localized surface plasmon resonance (SPR) of nanoparticles is caused by 
changes in the dielectric environment associated with the addition of PC-miR-148b to the HPC-
SNPs as predicted by Mie Theory.[50, 51] Salt aging functionalization techniques and absorption 
 96 
of ligands to the SNP surface results in an increase in the dielectric constant of the local 
environment typically causing a red shift in the SPR absorption band.[52]  
TEM analysis of HPC-SNPs and PC-miR148b functionalized SNPs (Figure 3.5 C and D) 
also indicates the attachment of PC-miR-148b to SNPs. PC-miR148b-SNP conjugates were 
observed to be partially surrounded with less dense regions attributed to adsorbed PC-miR-148b 
and associated salts (Figure 3.5D).  These less dense regions may be affected by Joule heating 
from e-beam irradiation resulting in melting and deformation of crystallized salt and RNA on the 
particle surface. Based on the DLS measurements the size of the SNPs decreased from 85.57 ± 
0.93 nm to 75.37 ± 0.83 nm with the attachment of PC-miR-148b to form PC-miR-148b-SNP 
conjugate, which is likely associated with the displacement of bulky HPC polymer 
(~80,000MW) with smaller miRNA mimic construct during the in-place exchange.  
 
Figure 3.5. Concept and characterization of SNPs and PC-miR148b-SNP conjugates. (A) 
Schematic of caged oligonucleotide-functionalized SNPs (HPC-SNP+ PC-mir148b).  (B) 
Absorbance spectra for SNPs and PC-mir148b-SNP. (C and D) TEM images of SNP and PC-
mir148b-SNP respectively.  
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A change in zeta potential was also observed after functionalizing HPC with PC-miR-
148b. The potential decreased from -6.11 ± 3.57 to -39.3 ± 6.63mV which can be attributed to 
displacing the HPC from the nanoparticles with negatively charged oligonucleotide (PC-miR-
148b).   This shift to a more negatively charged surface will likely result in greater colloidal 
stability in aqueous solution, as seen previously in nucleic acid functionalized particle 
systems.[53] 
Oligonucleotide coverage on the conjugate is an important factor, as it plays a role not 
only in stabilizing the conjugate, but also in the efficiency of nucleic acid payload delivery, in 
this case, the osteogenic miR-148b mimic. The salt aging functionalization process was adapted 
from previously described gold functionalization methods and optimized for the protected RNA 
mimics used in this study.[54] In addition to determining the total miRNA-148b mimic attached 
to the particle, the efficiency of photo-release was determined in an effort to quantify the 
effective dose for hASCs differentiation. [55] The attached PC-miR-148b was removed from the 
conjugate either by photoactivation (365nm) or treatment with DTT. A fluorescence-based 
method, in conjunction with inductively coupled plasma optical emission spectroscopy,  was 
used to calculate the coverage density and oligonucleotide footprint of PC-miR-148b. [56, 57] 
The miR-148b coverage density was 4.33 (±2) x 10
16 oligos/cm2 while the oligonucleotide 
footprint was 23.10 ± 20 nm
2
 as determined using the concentration values derived from DTT 
treatment. These oligo ratio and footprint values are comparable to previously published values 
for similar sized gold and silver nanoparticles.[57, 58] 





, a significantly lower in value than determined by DTT treatment.  These numbers 
correspond to PC-miR-148b/SNP ratio of 1361 ± 101.36 and 499.47 ± 47.0 oligonucleotide per 
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particle for DTT and UV radiation respectively. Due to the large variation in the amount of 
released PC-miR-148b from these two methods, we confirmed the oligonucleotide/particle ratio 
by treating the previously photoactivated sample with DTT to remove the remaining PC-miR-
148b from SNPs, resulting in a value of 720.30 ± 69.9 oligos/particle. It appears the additional 
DTT treatment successfully removed the bulk of the remaining oligonucleotide from the 
conjugate, as the combined total of 499.47 ± 47.0 (photocleavage) and 720.30 ± 69.9 (post PC 
DTT treatment), is indeed close to ~1300 recovered by DTT treatment alone.   From these results 
we can deduce that DTT released PC-miR-148b more efficiently than photoactivation, which is 
not unexpected based on previous studies of oligo photocleavage[58]  and nanoparticle 
stability.[53]  
3.4.3 Photomodulated Upregulation of ALPL 
 
ALP is one of the early protein enzymes expressed during osteogenesis and is displayed 
on the extracellular portion of the plasma membrane, resulting in increased local concentration of 
inorganic phosphate, a mineralization promoter, and decreased concentration of extracellular 
pyrophosphate, an inhibitor of mineral formation.[59] hASCs ALP expression was evaluated 
both qualitatively and quantitatively as a function of light activation after treatment with PC-
miR-148b-SNP conjugates. Control groups included; miSpike-21mer (universal control), stromal 
media (SM) control and photoexposed hASCs while test groups are osteogenic media (OM) 
control, SM with single stranded cationic agent transfected miR148b mimic and OM with single 
stranded miR148b mimic. Figure 3.6 demonstrates the degree of ALP enzyme activity when 
hASCs were treated under different conditions. The control groups (Figure 3.6A, B and C), 
exhibit minimal ALP activity on the hASCs, and are poorly stained as seen by the normalized 
absorbance/number of hASCs ratio in Figure 3.6K. hASCs treated with test group demonstrated 
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increased ALP enzyme activity based on the appearance of  darker staining (Figure 3.6D, E and 
F). The PC-miR-148b mimic and PC-miR-148b mimic+flashed sample (Figure 3.6G and H) did 
not upregulate ALP production and their normalized absorbance was similar to the control group. 
The major and most prominent upregulation of ALP was seen in PC-mir148b-SNP+flashed 
sample. The difference in enzyme activity can be appreciated while comparing the flashed and 
unflashed pair in Figure 3.6I and 3.6J where the normalized absorbance increased from 0.64 ± 
0.07 to 2.50 ± 0.06. The photoactivation facilitated the release of PC-miR-148b from the 
conjugate, initiating the osteogenic differentiation of hASCs. The absorbance value of PC-
miR148b-SNP+flashed differs significantly from SM ( value of 0.94 ± 0.05, p < 0.05; one-
sample t-test) but insignificantly from OM (value of 2.62 ± 0.04, p > 0.05; one-sample t-test).  
The ALP up-regulation was further quantified with Q-PCR and the -ΔΔCt value relative 
to SM, is plotted in Figure 3.7. The control group have a negative -ΔΔCt value while the test 
groups, OM and SM+miR-148b, have a -ΔΔCt  value of 2.42 ± 0.06 and 5.64 ± 3.9 after 7 days 
of transfection respectively. More importantly, the ALP -ΔΔCt value significantly increased to 
1.65 ± 0.29 when the PC-miR148b-SNP conjugate was photoactivated, compared to a value of -
6.3 ± 0.10 for non-light exposed controls. While this value is significantly lower than the OM 
control (p<0.05; one-sample t-test), the hASCs treated with the conjugate up-regulated the ALP 
production after light exposure arguing for a release of PC-miR-148b from the particle surface. 
The plasma membrane of osteoblasts are rich in ALP [60] and detection of high levels of ALP in 
cells treated with active conjugates indicate the presence of maturing osteoblasts in culture. ALP, 
expressed early in process of calcification, declines later in the developmental program when 





Figure 3.6 The hASCs treated were stained with ALP kit after treatment with (A) miSpike-
21mer, (B) Stromal Media (SM),  (C) SM and Flashed, (D) Osteogenic Media (OM), (E) SM+ 
miR148b, (F) OM+ miR148b, (G) PC-miR148b, (H) PC-miR148b + Flashed, (I) PC-miR148b-
SNP and (J) PC-miR148b-SNP + Flashed. Magnification is 20x, and scale bar is 100um. (K) 
ALP produced by the cells after being treated with varying condition was then quantified by 
absorbance/Number of hASCs. § denotes significantly different (p<0.05; one-sample t-test). ** 






Figure 3.7. Alkaline Phosphatase, expression was quantified by qRT-PCR, ΔCt value of each 
sample was calculated compared its human 18s rRNA control. The graph represents the - Δ ΔCt 
value of each sample calculated by the ΔΔCt method, with comparison to SM sample. § denotes 
significantly different value (p<0.05; one-sample t-test) while ** denotes insignificantly different 
(p>0.05; one-sample t-test) values. 
 
3.4.4 Mineralization of hASCs and Up-regulation of OCN and RUNX2 
 
During mineralization, osteoblasts produce extracellular calcium deposits, which are an 
indication of bone formation. In this study calcium deposition was measured by Alizarin Red S 
staining and visualized on hASCs treated under different conditions at the 14 day time point 
(Figure 3.8). hASCs treated with miSpike-21mer, stromal media and photo-exposed hASCs 
served as control groups (Figure 3.8A, B and C), and showed minimal calcium deposition 
quantified in image 3.8K.  hASCs treated with osteogenic media, SM with single stranded miR-
148b mimic and OM with single stranded miR-148b mimic controls (Figure 3.8D, E and F) had 
increased red staining indicating calcium deposition confirmed by the increased  normalized 
absorbance/number of hASCs ratio in image 3.8K. A clear increase in Alizarin Red S staining of 
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hASCs can be seen after photo-activating the conjugate to release PC-miR-148b from the SNPs 
(Figure 3.8I and 3.8J) where the normalized absorbance increased from 9.6 x 10
-6





  ± 7.11 x 10
-6
. The absorbance value of PC-miR148b-SNP+flashed differs 
significantly from SM (p < 0.05; one-sample t-test) but insignificantly from OM (p > 0.05; one-
sample t-test).  
As can be seen from the no-light control the conjugate can remain inactive for a period of 
at least 14 days unless the payload is released by radiation.  It is likely, that without photoclevage 
and release the miRNA payload is degraded after several days through hydrolysis and/or 
enzymatic degradation.  The amount of PC-miR-148b released from the conjugate via photo-
exposure is ~two fold less than the amount released by DTT but is sufficient initiate the 
osteogenic differentiation of hASCs. Similar to previously published studies, the progression of 
in vitro osteogenesis is characterized by decreased cellular proliferation followed by increased 
calcium deposition over time.[62] 
To further characterize the differentiation of hASCs transfected with conjugate, the up-
regulation of two well-documented middle and late stage osteogenic mRNA markers, RunX2 and 
OCN, was measured by Q-PCR at day 28. Activated conjugate-treated hASCs show a 6.41 ± 
1.14 RunX2 -ΔΔCt value compared to SM control, after 365nm photoexposure, which is not 
significantly different from OM, but is significantly different from SM+miR-148b controls. The 
-ΔΔCt value increases from -4.24 ± 2.44 to 6.41 ± 1.14 with the light activation of the conjugate 
(Figure 3.9A). Similar trends are followed in the OCN upregulation where the - ΔΔCt value of 
active conjugate (10.61 ± 3.53) is significantly different from its inactive form (-0.71 ± 2.4) and 
SM+miR-148b (4.41 ± 0.73) and significantly different from OM (7.97 ± 0.26) (Figure 3.9B). 
The mineralization of extracellular matrix correlates with the expression of OCN, osteopontin 
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(OPN), RunX2 and bone morphogenetic proteins (BMP). [63, 64] BMPs initiate osteogenesis by 
activating the transcription of core binding factor a1 (RunX2), which then stimulate the 
osteoblast-specific genes such as ALP and OCN by binding to the osteoblast-specific cis-acting 
element 2 (OSE2) in the promoter region of these genes.[60] Marked increase in the levels of 
ALP, OCN and RunX2 mRNA expression further indicates the osteogenic differentiation of 
hASCs with activated HPC-SNP + PC-miR148b. 
 
 
Figure 3.8. The mineralization of hASCs was quantified by staining cells with Alizarin Red. The 
conditions of treatment are (A) mispike-21mer, (B) Stromal Media (SM), (C) SM and Flashed, 
(D) Osteogenic Media (OM), (E) SM+ miR148b, (F) OM+ miR148b, (G) PC-miR148b, (H) PC-
miR148b + Flashed, (I) PC-miR148b-SNP and (J) PC-miR148b-SNP+ Flashed. Magnification is 
20x, and scale bar is 100um. (K) Mineralization of hASCs was quantifierd after being treated 
with varying condition was then quantified by absorbance/Number of hASCs. § denotes 




Figure 3.9. Up-regulation of late-stage osteogenic markers, osteocalcin (OCN) and RunX2 was 
quantified by qRT-PCR. ΔCt value of each sample was calculated compared its human 18s 
rRNA control. The graph above represents the (A) RunX2 and (B) OCN - Δ ΔCt value of each 
sample calculated by the ΔΔCt method, compared to SM sample. § denotes significantly different 
values (p<0.05; one-sample t-test) while ** denotes an insignificantly different values. (p>0.05; 
one-sample t-test)  
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3.4.5 Measuring in vitro Photo-release of PC-miR-148b with Confocal Microscopy  
 
The release of PC-miR-148b was semi-quantitatively measured using confocal images of 
hASCs transfected miR-148b mimics using TurboFect or with the PC-miR148b-SNP conjugates 
(Figure 3.10). Panels b and c show the reflectance mode image of SNPs (488nm/498nm) and 
fluorescence of 6-TAMRA (531nm/572nm) respectively. Figure 3.10 (1a-1d and 2a-d) show the 
results of PC-miR-148b transfection into hASCs with TurboFect. The photoexposure does not 
appear to have any impact on the spatial distribution of the 6-TAMRA fluorescence in TurboFect 
transfected cells (compare Panel 1c and 2c), indicating that no intracellular redistribution of the 
6-TAMRA labeled microRNA occurs as a result of light exposure. In contrast, delivery of PC-
miR-148b-SNP conjugates to the intracellular environment was achieved without the use of 
transfection vectors (Panel 3a-3d and 4a-4d). The resulting fluorescent distribution is similar to 
that seen with TurboFect delivered PC-miR-148b (Panel 1a-1d and 2a-2d). Overlay of particle 
reflectance with TAMRA-labeled oligonucleotide fluorescence was used to calculate co-
localization coefficients (Mander‟s Coefficient).[65] The images in Figure 3.10 (Panel 3d and 
4d) indicate the change in co-localization of the SNPs reflectance and 6-TAMRA fluorescence as 
a result of photo exposure in PC-miR-148b-SNP. The Mander‟s Coefficient for images 3d and 
4d are 1 and 0.73 respectively. The PC-miR-148b-SNP conjugate with no light expsoure had 
100% co-localization while UV radiation treatment correlate with a decreased colocalization 
SNPs reflectance and 6-TAMRA fluorescence of 73%. Based on the photorelease quantification  
studies described above some PC-miR-148b is expected to remain tethered to the particle with 





Figure 3.10 (1) PC-miR-148b, (2) PC-miR-148b+UV radiation, (3) PC-miR-148b-SNP and (4) 
PC-miR-148b-SNP+flashed delivery to hASCs to study the photo-release of oligonucleotide 
from the conjugate. Images depict (a) Brightfield views, (b) silver particle reflectance 
(488nm/598nm), (c) 6-TAMRA fluorescence (531/572nm) and (d) Reflectance + Fluorescence 
overlay. The Mander‟s Coefficient for images 3d and 4r are 1 and 0.73 respectively. 
Magnification is 63x, and scale bar is 12um.  
 
3.4.6 OCN ELISA Expression 
 
Osteocalcin is synthesized only by the osteoblast and although the majority of the 
synthesized osteocalcin is deposited into bone matrix at the time of bone mineralization, a  small 
amount of OCN can be detected in serum[66, 67]. Therefore, it is expected that mature OCN 
protein can be detected in the conditioned culture media used for hASCs culture and 
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differentiation using an enzyme-linked immunosorbent assay (ELISA). The hASCs were treated 
with PC-miR148b-SNP and activated with UV radiation along with experimental and control 
groups detailed in section 2.3 for 14 and 28 days. The conditioned media from the final four days 
of culture were used for OCN protein expression determination. The concentration of OCN in 
ng/ml was normalized to the number of hASCs measured by PicoGreen.  Light exposure of 
hASCs cultured with PC-miR-148b-SNP conjugates correlates with an increase in OCN protein 
expression (Figure 3.11) at 28days. The OCN levels detected from media of PC-miR148b-SNP 
treated hASCs increased from 0.004 ± 0.0007 to 0.0065 ± 0.003 with photoexposure. The value 
for SM + miR148b was 0.0065±0.001 which is not significantly different from non 
photoexposed PC-miR148b-SNP (p>0.05; one-sample t-test). In the OM media extract the OCN 
levels decreased from from 0.0059 ± 0.004 to 0.005 ± 0.0003 from 14 to 28 days respectively, 
indicating that induction of osteogenesis by OM and photoactivated PC-miR148b-SNP may 
result in differences in the time course of osteogenic marker expression. The OCN levels in the 
14days OM was not significantly different from PC-miR148b-SNP (p>0.05; one-sample t-test). 
The control groups, SM and miSpike-21mer, had significantly lower values than from PC-
miR148b-SNP value (p<0.05; one-sample t-test). This protein expression data is correlates with 
visual observation that mineralized nodules form in hASC cultured in OM as early as 14 days 
while this processes is temporally retarded in photoexposed PC-miR148b-SNP treated cells (data 
not shown). While this difference in timing of maximum OCN expression is interesting, the 
underlying cause is unclear. It is possible that this is miR148b mimic concentration related 
phenomena, i.e that increasing PC-miR148b-SNP dose will result in increased OCN 
concentration at day 14. Alternatively, osteogenic differentiation initiated by OM and miR148b 
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mimic may work through similar but not identical pathways. Future efforts will further explore 
this phenomenon. 
 
Figure 3.11. The cell media was collected and evaluated for OCN secretion by ELISA by 
measuring the 450 nm absorbance and quantifying with a standard curve. The amount of OCN 
(ng/ml) was then normalized to the numbe of hASCs measured by PicoGreen. § denotes 
significantly different (p<0.05; one-sample t-test) values while** denotes an insignificantly 
different values (p>0.05; one-sample t-test). 
 
3.4.7 Cytotoxicity of PC-miR148b-SNP 
 
 The cytotoxicity of PC-miR148b-SNP was compared to appropriate controls via flow 
cytometry scatter and fluorescence analysis using Sytox Red exclusion as a live/dead reporter.  
Cells were analyzed after 28 days in culture and cells treated with the PC-miR148b-SNP 
construct showed little cytotoxic response in both light exposed and non exposed conditions 
(Figure 3.12). Light exposure and SNP treated hASC controls also demonstrated little reduction 
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in viable cell counts. The concentration of PC-miR148b and the SNPs, in the conjugates, was 
matched to the concentrations used in drive the osteogenic differentiation of hASCs in previous 
experiments. At these concentrations, 96.97 ± 1.5 % and 92.85 ± 5.24 % of hASCs were viable 
when exposed to PC-miR148b and HPC-SNPs respectively. Also the PC-miR148b-SNP 
conjugates showed minimal cytotoxicity regardless of light treatment as 90.68 ± 3.64% and 
90.08 ± 2.12 % of hASC cells were viable in the non and photo-activated groups respectively. It 
should also be noted that the photo-activation via UV radiation had a non-significant effect of the 




Figure 3.12.  Normalized Viability of hASCs when exposed to different conditions. The percent 
viability of each sample was measured with Sytox Red and normalized to live control. 
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3.5 Discussion  
Oligonucleotides caged with photocleavable compounds have been successfully used in 
the laboratory to modulate gene expression in zebrafish for developmental studies[68-71]_ 
precisely apply gradients of gene silencing [72] and better understand and create synthetic 
genetic circuits[73]. This technology can potentially one day be uniquely suited for optically-
accessible clinical applications as it is recognized that this light activated miRNA delivery 
technology is generally limited to UV light accessible tissues such as the dermal, mucosal 
membrane, retinal, dental and maxillofacial tissues and pulmonary cases (reviewed in [74]). 
Without direct fiber delivery approaches, the penetration depth of photoactivating UV 
wavelengths into biological samples is very limited (as demonstrated in [75],) but doses can be 
optimized to achieve photoactivation in vitro[74] and in vivo[76] without significant biological 
damage. We suggest that additionally there is a potential orthopedic application in the surgical 
repair of trauma, joint replacement and wound beds where deep tissues are light accessible at the 
time of surgery. Consequently, the PC-miR-148b-SNP construct would permit fine 
spatial/temporal control of cell differentiation and tissue repair leading to improved clinical 
outcomes.  
While the PC-miR-148b-SNP construct or cells transfected with these constructs may 
diffuse in vivo, they appear to remain inert until photoactivated, as demonstrated by differences 
between ALP, RunX2 and OCN expression in light exposed and non-exposed PC-miR148b-SNP 
conjugate treated hASCs. Additionally, since miRNA are short lived and only transiently 
modulate mRNA expression, it is expected that there is little chance of permanent activity once 
an activated cell has begun differentiation. The miRNA associated with inactivated construct are 
expected to degrade slowly intracellularly or in the intercellular space through enzymatic action 
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or hydrolysis, reducing the potential spurious activtion resulting in heterotopic ossification of 
non-target tissues. The preliminary in vitro toxicity study demonstrated that at the osteogenic 
dose, PC-miR-148b-SNP show minimal cytotoxicity, comparable to controls, when transfected 
into hASCs. The normalized viability of all the samples was not significantly different from live 
control. Based on the current understanding of the systems‟ function and the data presented 
above, it is expected that PC-miR-148b-SNP construct may have advantages over current state of 
the art drug eluting bone-grafts and gene delivery vectors.  
To translate this technology into a clinical setting, PC-miR148b-SNP conjugate 
containing hASCs will be loaded on a three dimensional (3D) natural or synthetic matrix and 
either photoactivated pre or post in vivo implantation. Our preliminary study demonstrated the 
UV penetration capability and photoactivation of PC-miR148b-SNP in a polycaprolactone (PCL) 
scaffold. The miR148b was released from the conjugate, driving hASC differentiation resulting 
in mineralization of the scaffolds. 
Oligonucleotides caged with photocleavable compounds have been successfully used in 
the laboratory to modulate gene expression in zebrafish for developmental studies[68-71]_ 
precisely apply gradients of gene silencing [72] and better understand and create synthetic 
genetic circuits[73]. This technology can potentially one day be uniquely suited for optically-
accessible clinical applications as it is recognized that this light activated miRNA delivery 
technology is generally limited to UV light accessible tissues such as the dermal, mucosal 
membrane, retinal, dental and maxillofacial tissues and pulmonary cases (reviewed in [74]). 
Without direct fiber delivery approaches, the penetration depth of photoactivating UV 
wavelengths into biological samples is very limited (as demonstrated in [75],) but doses can be 
optimized to achieve photoactivation in vitro[74] and in vivo[76] without significant biological 
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damage. We suggest that additionally there is a potential orthopedic application in the surgical 
repair of trauma, joint replacement and wound beds where deep tissues are light accessible at the 
time of surgery. Consequently, the PC-miR-148b-SNP construct would permit fine 
spatial/temporal control of cell differentiation and tissue repair leading to improved clinical 
outcomes.  
While the PC-miR-148b-SNP construct or cells transfected with these constructs may 
diffuse in vivo, they appear to remain inert until photoactivated, as demonstrated by differences 
between ALP, RunX2 and OCN expression in light exposed and non-exposed PC-miR148b-SNP 
conjugate treated hASCs. Additionally, since miRNA are short lived and only transiently 
modulate mRNA expression, it is expected that there is little chance of permanent activity once 
an activated cell has begun differentiation. The miRNA associated with inactivated construct are 
expected to degrade slowly intracellularly or in the intercellular space through enzymatic action 
or hydrolysis, reducing the potential spurious activtion resulting in heterotopic ossification of 
non-target tissues. The preliminary in vitro toxicity study demonstrated that at the osteogenic 
dose, PC-miR-148b-SNP show minimal cytotoxicity, comparable to controls, when transfected 
into hASCs. The normalized viability of all the samples was not significantly different from live 
control. Based on the current understanding of the systems‟ function and the data presented 
above, it is expected that PC-miR-148b-SNP construct may have advantages over current state of 
the art drug eluting bone-grafts and gene delivery vectors.  
To translate this technology into a clinical setting, PC-miR148b-SNP conjugate 
containing hASCs will be loaded on a three dimensional (3D) natural or synthetic matrix and 
either photoactivated pre or post in vivo implantation. Our preliminary study demonstrated the 
UV penetration capability and photoactivation of PC-miR148b-SNP in a polycaprolactone (PCL) 
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scaffold. The miR148b was released from the conjugate, driving hASC differentiation resulting 
in mineralization of the scaffolds (Supplementary Figures: S5). 
3.6 Conclusions 
The findings herein concur with previous studies demonstrating the osteogenic potential 
of miR-148b mimic and further, it indicates that both miR-148b and miR-148b* mimic sub-
sequences have discrete osteogenic properties.   A facile in-place exchange method is described 
for the synthesis of PC-miR-148b-SNP conjugates for use as photo-activated miRNA particles. 
Light mediated spatial and temporal control of miR-148b mimic activation was demonstrated by 
driving hASCs osteogenic differentiation using the PC- miR-148b -SNP conjugate.  The UV 
light was demonstrated to release PC-miR-148b from the conjugate and histological staining of 
cells showed the upregulation of alkaline phosphatase and the mineralization of hASCs when 
cultured with PC-miR148b-SNP conjugate and photoactivated. The up-regulation of ALP, OCN 
and RunX2, confirmed by Q-PCR, provides further support of osteogenic differentiation and 
indicates that miR-148b may drive osteogenesis through similar pathways modulated by OM. It 
was also shown that no-light control the conjugate remained inactive for a period of at least 14 
days unless the payload was released by radiation. Changes in co-localization of the particle and 
miRNA payload occurred as function of light activation, indicating photoclevage and miRNA 
release from the particle intracellularly. This proof-of-concept study demonstrates the potential 
of the PC-miR-148b-SNP conjugates as a light activated miRNA delivery vehicle and the 
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Chapter 4.  Light Activated miR-148b-Nanoparticle Conjugates Heal Critical 
Size Mouse Calvarial Defects 
 
4.1 Project Summary  
 
Targeted delivery and controlled release of oligonucleotide therapeutics in vivo are 
essential aspects of an ideal gene delivery vehicle. Delivery systems providing spatial and 
temporal control have the potential to improve outcomes in surgical reconstruction and 
regenerative medicine by precise modulation of wound healing and tissue repair processes. We 
combined this technique with human autologous progenitor cells and used microRNA (miRNA) 
to modulate gene expression for improved closure of a critical size defect drilled on the left 
parietal bone of the male CD-1 nude homozygous mice. The hASCs loaded scaffold were 
incubated with PC-miR-148b-SNP conjugates and activated prior to implantation. After 4 and 12 
weeks, the 3D u-CT reconstructed images showed the percent bone headlining increased from 
3.83 ± 1.19 to 6.54 ± 4.28 and 10.91 ± 5.45 to 22.30 ± 4.93 for non-photoactivated and 
photoactivated conjugates respectively. The osteogenic differentiation of hASCs, with photo-
released miR-148b, supported by the scaffold assisted in the closure of the defect. The results 
were confirmed with H&E and Masson‟s Trichrome stains in the transverse sections of 
photoactivated conjugates, the collagen fiber lining thickened the most at 12 weeks and was of 
the same density and thicknesses as the pre-existing calvarium. Mineralization of the new bone 




Skeletal homeostasis is an active process that involves the balancing function of multiple 
factors affecting the metabolic activity of pre-osteoblasts. Growth factors like IGFs or TGFβs are 
released during resorption and initiate local bone formation[1, 2] while other factors deposited on 
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the bone surface by osteoclasts at the end of bone resorption initiate the following phase of bone 
formation.[3] Other factors like parathyroid hormone and prostaglandin E can act 
complementary to each other and stimulate both bone resorption and bone formation. Apart from 
these factors, other cytokines and hormones mediate the receptors on the osteoblast-lineage cells 
leading to maintenance of bone turnover by an effective osteoblast–osteoclast interaction.[4] 
Skeletal cells synthesize several growth factors including bone morphogenetic proteins (BMPs) 
that induce osteogenic differentiation of mesenchymal cells. On the molecular level, exposure of 
appropriate microRNAs (miRNA), non-coding RNAs involved in post-transcriptional regulation 
pathways and often associated with RNA silencing complexes, can be used to modulate the 
osteogenic differentiation of human adipose derived stem cells (hASCs)[5-7]. This technique 
could serve as an attractive therapeutic modality for regenerative medicine and is of particular 
interest in the design of therapies for critical size bone defects, spinal fusion and skeletal 
reconstruction. 
Currently, allogenic or autogenic graft materials are widely and successfully used for the 
repair of skeletal bone defects but this technique has disadvantages including rejection, infection, 
limited supply and donor site morbidity due to operation respectively.[8] Adipose tissue is an 
abundant and accessible source of stromal/stem cells that is isolated from patients commonly 
through liposuction surgeries. The lipoaspirate is digested by collagenase and multiple 
centrifugation steps. The derived multipotent hASCs have the potential to differentiate along the 
adipocyte, chondrocyte, myocyte, neuronal, and osteoblast lineages. These hASCs have potential 
applications for the repair and regeneration of acute and chronically damaged tissues if activated 
with appropriate inductive factors.[9] 
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Our previously described light activated miRNA delivery system,  with demonstrated 
capability, in vitro, to upregulate  alkaline phosphatase (ALP) and osteocalcin (OCN) and 
mineralization of hASCs[10], will provide greater temporal and spatial control over the 
activation of differentiation and potentially improve healing of critical size defects. The hASCs 
transfected with light activated-miR-148b delivery conjugates will remain inert until activated 
with light. Additionally, since miRNA are short lived and only transiently modulate mRNA 
expression, it is expected that there is little chance of permanent activity once an activated cell 
has begun differentiation.  
To study the bone formation due to osteogenic factors in vivo many rodent models have 
been used. On a molecular level, cells homogeneously expressing green fluorescent protein 
(GFP) can labeled and tracked [11, 12] while the physical models range from axial loading of 
tibia[13] to closure of critical size defects (CSD)[14, 15]. Previously, CSD models have been 
used for both the evaluation of normal healing, and the use of ASCs for the healing of critical 
sized (or non-healing) defects.[15] Here we have adapted this previously described CSD model 
for the evaluation healing in conjunction with hASCs transfected with light activated miRNA-
148b-SNP conjugates.  
Researchers have widely reported the therapeutic advantages of delivering stem cells 
with appropriate growth and inductive factors in biodegradable scaffolds providing appropriate 
physiological environments.[16-18] To evaluate the potential of this light activated miRNA 
delivery system to modulate CSD healing, we loaded hASC transfected with miRNA-148b-SNP 
conjugates on to scaffolds composed of polycaprolactone (PCL) as it has  been previously 
demonstrated to have little impact on hASC differentiation. The in vivo osteogenic capability of 
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hASCs and bone formation once induced by our light activated miRNA-148b-SNP conjugates 
was histologically tested and through microCT analysis.[19] 
4.3 Materials and Methods 
4.3.1 Dosage Dependence Mineralization 
 Varying concentrations of PC-miR-148b-SNP conjugates (10-100ul of 227.2 ±1.7 ppm 
SNP or 0.120-1.20nM) were added to hASCs and ALPL upregulation and mineralization of 
hASCs was tested at day 7 and 14 respectively. The ALPL up-regulation was qualitatively and 
quantitatively measured by Millipore kits, SCR 004 and SCR 066 while the mineralization of the 
cells was quantified with Alizarin Red S stain 
4.3.2. Calvarial Size Mouse Defects 
All animal studies were purchased from Jackson Laboratory and housed in the LSU Life 
Sciences Vivarium on the Louisiana State University campus. The Animal Facility was accessed 
only by the authorized personnel that follow PPE protocols and its temperature, ventilation and 
illumination was controlled. The animal study was approved by LSU IACUC, protocol # 13-004. 
In vivo studies were conducted on adult (42 day –old) male CD-1 nude homozygous mice 20-40g 
(Jakckson Laboratory J:NU Stock Number: 007850). Surgery and all peri-operative procedures 
were conducted at LSU Veterinary School and transported to the LSU Life Science Vivarium 
where the mice were maintained and evaluated periodically till euthanized after 12 weeks.  The 
guidelines for Transportation of animals from Louisiana State University were thoroughly 
followed. 
To avoid incompatibility of xenografted human tissue, an athymic mouse served as the 
model organism. Briefly, non-healing, critical-sized calvarial defects (4 mm) were created in the 
left parietal bone of adult male CD-1 nude mice using a high-speed 4.6 OD Trephine Bur (ACE 
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Surgical, Brockton, MA) and saline irrigation. Animals were anesthetized with inhalant 
isoflurane. After disinfection, an incision was made just off the sagittal midline to expose the left 
parietal bone. Unilateral full-thickness critical-size calvarial defects were created in the non-
suture associated left parietal bone, while the dura mater is left undisturbed. The surgical sites 
were stapled and the animals were monitored per established post-operative animal care 
protocols.  
In preparation for implantation, Polycaprolactone (PCL) (4mm dia and 1mm thick) 
scaffolds were synthesized as previously described by Qureshi et al [20] and seeded with hASCs. 
1.0-1.5 x 10
5
 cells were resuspended in 20 ul of stromal media (DMEM, 10% FBS, 1% 
penicillin/streptomycin) and seeded on the PCL scaffolds by pipetting 10 ul of cells on top of 
each side. The scaffolds were then incubated at 5% CO2 and 37°C for 2 hrs before submerging it 
in 300 ul of stromal media for 24 hrs prior to PC-miR-148b-SNP construct treatment. 10 ul of 
PC-miR148b-SNP construct (227.2 ± 1.7 ppm SNP and 40 nM PC-miR-148b) was added to 
scaffolds for 16 hr before photo-release. For photo-release, the PC-miR148b-SNP treated 
scaffolds were photo-activated for 5 min at 365nm (52.4 J/cm
2
) by means of a GreenSpot system 
(Figure 4.1). Animals were split into two experimental groups, two positive and three negative  
controls and were tested for closure of the defect at 4 and 12 weeks. The experimental groups 
included 1) PCmiR-148b-SNP and 2) PCmiR-148b-SNP + UV (n= 6 each) while negative 
controls included 1) PCL scaffold only, 2) empty defect only and 3) scaffold with miSpike-
21mer (n=2 each). The positive controls included 1) scaffold with hASCs and 2) defect with 
osteogenic scaffold (n=6 each) (Table 4.1). Before implantation, cell-seeded scaffolds were 
rinsed in sterile PBS to prevent transfer of medium derived growth factors or immunogens. After 
implantation, animals were allowed to recover under heating pads for one hour before being 
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returned to the animal facility. Thereafter, animals were observed once daily for three days and 
weekly thereafter to ensure postoperative recovery (Figure 4.2). 




Figure 4.1. Procedure for calvarial size defect surgery preparation. The hASCs are loaded on 
PCL scaffolds and after 24 hrs the PC-miR148b-SNP conjugates are added on the scaffolds. The 
scaffolds are activated with UV and implanted on the CD-nude mice.   
 
 4.3.3. In Vivo Imaging 
 
The animals were sacrificed by CO2 asphyxiation and cervical dislocation was conducted 
to study the growth of skeletal bone with the light activated miR-148b-SNp conjugates. Micro 
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computed tomography was performed, using SkyScan 1074 tomography imaging system (Micro 
Photonics, Allentown, PA, USA). The following settings were used: 40 kVp polychromatic x-ray 
beam; field of view of 28 mm in diameter and 19 mm in height, current of 1000uA and an 
exposure time of 420 milliseconds for each of the 360 rotational steps. The 2D projection images 
were used to reconstruct tomograms with a commercial package (Avizo 8, Mercury Computer 
Systems, Berlin, Germany).  Percentage healing in the region of the defect was evaluated using 
Image J (NIH, Bethesda, MD). 
 
 
Figure 4.2. Calvarial size defect surgery was conducted under LSU IACUC-13-004 protocol. (A) 
4mm defects were drilled into the parietal bone of adult male nude mice using high speed drill 
for LAMD implantation, (B) The PCL scaffold was implanted in the defect (C) the mice were 
anesthetized using isoflurane and (D) the surgical site was stapled with Michel clips.  
 
4.3.4 Histological Staining 
Following radiographic imaging calvaria were processed and stained as described 
previously.[14, 15] Briefly, the calvaria were harvested, fixed in 10% formalin for 24 hr, 
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decalcified in with 10% Ethylenediaminetetraacetic acid (EDTA) for three days and embedded 
into paraffin wax for sectioning. To evaluate bone regeneration, 10um sections were cut and 
stained with H&E and Masson‟s Tirchome (American MasterTech, Lodi- CA, Item # 
KTTRBPT) according to manufacturer‟s protocols (collagen appears pink and blue under H&E 
and Masson‟s Tirchome stains respectively). The sections were imaged using Olympus BX46 
microscope. 
4.3.5 Ex vivo Mineralization of Scaffolds 
To confirm the in vivo mineralization of PCL scaffolds with the PC-miR-148b-SNP in 
the mice, the scaffolds were prepared as previously described in section 4.3.1. Instead, the 
scaffolds were submerged in stromal media for 4 or 12 weeks while exchanging the media every 
3-4 days. The mineralization was quantified with Alizarin Red S stain as previously described by 
Qureshi et. al[10].  
4.3.6 Statistical Analysis 
All results were expressed as mean ± error. Data was analyzed with one way t-test. For 
all comparisons, a p-value < 0.05 was considered significant. 
4.4 Results  
4.4.1 Osteogenic Differentiation with Varying Concentrations of PC-miR-148b-SNP 
Conjugates 
 
Prior to implantation of scaffolds with PC-miR-148b-SNP conjugates in mice, the 
optimal concentration of conjugates that is non-cytotoxic to hASCs and has the maximum 
differentiation potential was tested by exposing varying concentrations of conjugates to cells for 
7 and 14 days.  
ALPL is one of the early protein enzymes expressed during osteogenesis and is displayed 
on the extracellular portion of the plasma membrane, resulting in increased local concentration of 
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inorganic phosphate. The negative controls, Stromal media (SM) and SM+Flashed, exhibited 
minimal ALPL activity on the hASCs (Figure 4.3 A and E) while a trend, quantified in Figure 
4.3 (I), was observed with increasing concentration of conjugates. The most significantly 
different ALPL production was seen between the 10ul photo and non-photoactivated conjugate 





 to 2.3 x 10
4
 ± 2.4 x 10
5
 when activated with UV radiation (p<0.05; one-sample t-test). 
The ALPL absorbance of UV activated 0.60 nM and 1.20 nM of conjugate samples were not 
significantly different from each other (p>0.05; one-sample t-test) and lower than activated 0.12 
nM conjugate sample due to a decrease in the number of viable cells. The higher concentrated 
samples (0.60 nM-1.20 nM) were more cytotoxic to the cells seen by the visible differences in 
the morphology (Figure 4.3 C, D, G and H) and decrease in the number of hASCs after 7 days.   
A late stage of bone formation is the accretion of extracellular calcium deposits on ECM 
deposited by the osteoblasts. For this dosage dependence study, the calcium deposition was 
quantitatively and qualitatively measured by Alizarin Red S stain as hASCs were treated with 
varying concentrations of conjugates (Figure 4.4). The negative controls, Stromal media (SM) 
and SM+Flashed, had the least calcium deposition on hASCs (Figure 4.4 A and E). The 
calcification of hASCs increased sharply for the UV photoactivated 0.12 nM and 0.60 nM 





 and 9.80 x 10
4
 ± 4.3 x 10
7
 respectively. The 1.20 nM conjugate sample was cytotoxic 
to the cells and the lower number of hASCs resulted in the lower normalized absorbance/hASCs 
ratio. This was confirmed with the visual difference in the morphology of the hASCs with 1.20 
nM conjugate sample (Figure 4.4 D and H). It can be concluded that up to 0.60 nM SNP can be 
used for the differentiation of hASCs as higher concentrations can have a deteriorating affect on 
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the morphology and the viability of cells. The recommended and optimum concentration of 
conjugates was 0.60 nM as it is noncytotoxic and has the maximum osteogenic differentiation 
potential.  
 
Figure 4.3. Alkaline phosphatase (ALPL) upregulation of hASC exposed to varying 
concentrations of Pc-miR-148b-SNP conjugates. (A) Stromal Media (B) 0.120nM, (C) 0.60 nM, 
(D) 1.20 nM, (E) hASCs+ Flashed, (F) 0.120 nM + Flashed, (G) 0.60 nM + Flashed, (H) 1.20 
nM + Flashed and (I) Quantification of ALPL absorbance after 7 days. § denotes significantly 
different values (p<0.05; one-sample t-test) while ** denotes insignificantly different values 




Figure 4.4. Mineralization of hASCs with Alizarin Red S stain. hASC exposed to varying 
concentrations of Pc-miR-148b-SNP conjugates. (A) stromal media control  (B) 0.120nM, (C) 
0.60 nM, (D) 1.20 nM, (E) stromal+ Flashed, (F) 0.120 nM + Flashed, (G) 0.60 nM + Flashed, 
(H) 1.20 nM + Flashed and (I) Quantification of Alizarin Red absorbance after 14 days. § 
denotes significantly different values (p<0.05; one-sample t-test) while ** denotes insignificantly 
different values (p>0.05; one-sample t-test) 
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4.4.2 μ-CT Imaging 
 The 2D and 3D reconstruction of images taken of mice heads by μ-CT showed closure of 
the defect after 4 and 12 weeks for the experimental and test control groups (Figure 4.5- A). As 
expected, in the negative controls the bone regeneration and hence the defect closure was 
minimal even after 12 weeks post implantation; corresponding to the percent healing values of 
5.97%, 4.76% and 1.52 % for scaffold only, empty defect and scaffold+ miSpike-21mer 
respectively after 12 weeks. The positive controls with scaffold loaded with hASCs and 
maintained in stromal and osteogenic media for seven days prior to implantation had some bone 
regrowth. For scaffold+ hASCs, the percent closure of the defect was not significantly different 
between 4 to 12 weeks (the values changed from 4.5 ± 3.65 6.5 ± 0.80) while the in vitro 
osteogenic induction of the scaffolds in osteogenic media (DMEM, 10% FBS, 0.1 μM 
dexamethasone, 50 μM ascorbate-2-phosphate, 10 mM β-glycerophosphate, and 1% antibiotic) 
for 7 days prior to implantation increased the bone growth from 3.43 ± 1.22 to 13.7 ± 7.31 from 
4 to 12 weeks. The percent bone regeneration increased for both the experimental groups 
between 4 to 12 weeks; the PC-miR-148b-SNP conjugate percentage increased from 3.83 ± 1.19 
to 10.91 ± 5.45 while the percentage values for PC-miR-148b-SNP+UV increased from 6.54 ± 
4.28 to 22.30 ± 4.93. The UV activation of the PC-miR148b-SNP conjugate released the miR-
148b and differentiated the hASCs in the scaffolds but the percentage healing of the defect with 
photoactivated conjugates is lower than expected and can be further optimized to achieve higher 
closure of the defect. Also, the 12 weeks healing percentages of the experimental groups were 
not significantly different from each other. These in vivo results demonstrate a trend in the 
osteogenic differentiation of hASCs and formation of bone in the defect with the conjugates but 
the in vivo process of inducing osteogenic differentiation with these conjugates need to be 
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optimized to achieve higher percent closure of the defect. This will be achieved by increasing the 
number hASCs loaded to the scaffolds to 1.5 x 10
5 
cells/scaffold, increasing the conjugate 
dosage and increasing the number of mice for each experimental group to improve the 
significance of the values.  
We also observed the defect treated with non-photoactivated PC-miR148b-SNP 
conjugates to close to 10.91 ± 5.45% after 12 weeks and this can be reduced by proper handling 
of the scaffolds pre-implantation. For future surgeries, special care will be taken to minimize the 
light exposure during transporting the scaffold to surgery room and during the surgery to inhibit 
the release of miR-148b from the conjugates. As excess miRNA is added during the particle 
functionalization process, additional purification, to remove unbound PC-miR-148b, will very 
likely increase the differences in defect closure between photoactivated PC-miR-148b conjugates 
and non activated conjugates.   
4.4.3 Histological Analysis 
 
The mouse calvarium sections were decalcified with EDTA and the presence of collagen 
was studied with H&E and Masson‟s Trichrome stains. The images in Figure 4.6 track the 
changes in collagen lining across the defect between 4 and 12 weeks. Comparing the 4 and 12 
weeks images, the pink stained collagen lining remained consistently thin and minimal in the 
negative controls; scaffold only, empty defect samples and scaffold+hASCs (Figure 4.6 1a-3a 
and 1b-3b). For positive controls, scaffold+ hASCs (OM), the collagen lining appeared visibly 
thicker and mineralized with purple stained bone marrow present in the new bone (Figure 4.6- 
4b). The greatest difference was seen between the photo and non-photoactivated PC-miR-148b-
SNP conjugate samples. In the non-photoactivated sample, few strands of collagen fiber lining 
stretched across the defect site between the pre-existing calvarium but the mineralization is very 
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nominal (Figure 4.6-5a and 5b). For photoactivated PC-miR-148b-SNP conjugates, the collagen 
fiber lining can be seen thickening between 4 to 12 weeks (Figure 4.6-6a and 6b). The collagen 
lining thickened the most at 12 weeks and was of the same density and thicknesses as the pre-
existing calvarium and the positive controls.  
Similar trends were seen when the sections were stained with Masson‟s Trichrome. The 
intercellular fiber and collagen appear red and blue respectively. The negative control samples; 
scaffold only and empty defect samples, demonstrated the absence of collagen at the defect site 
(Figure 4.6-1c and 2c). Small blue stained collagen colonies were seen as the interface between 
the pre-existing bone and the defect site. Scaffold+hASCs samples show an increased presence 
of collagen at the interface but the lining does not span across the defect site. It was encouraging 
to see minimal closure/healing of the defect in these negative controls. The positive control 
group, scaffold+ hASCs (OM), showed an increased ossification greater than the pre-existing 
bone. After 12 weeks, the hASCs scaffolds mineralized completely due to osteogenic induction 
prior to implantation. The mineralized and ossified scaffolds had similar staining to the 
calvarium (Figure 4.6-4c). Differences in the amount of collagen and the mineralization of 
hASCs can be appreciated by comparing the stained sections of non-photoactivated and 
photoactivated PC-miR-148b-SNP conjugates (Figure 4.6-5c and 6c). The collagen strands 
thicken as the scaffolds mineralize with the photoactivation of conjugates.         
The osteogenic differentiation of hASCs, with photo-released miR-148b, occurred in the 
scaffold and assisted in the closure of the defect. These transverse sections of the new bone with 
photoactivated PC-miR-148b-SNP conjugate show abundant amount of collagen present at the 
defect site . Mineralization of the new bone can also be appreciated with few colonies of dark 




























































































































































































































































































































































































































































































4.4.4 Ex vivo Mineralization of Scaffolds 
 The mineralization of scaffolds loaded with hASCs and conjugates was quantified with 
Alizarin Red stain after 4 weeks (Figure 4.7). During mineralization, osteoblasts produce 
extracellular calcium deposits, which are an indication of bone formation. The negative controls 
(scaffolds with hASCs and scaffolds with miSpike-21mer) induced minimal mineralization of 
the scaffolds but the positive control, scaffolds with hASCs in OM, showed a significantly higher 
mineralization (0.21 ± 0.008). The difference in the mineralization values between the non-
photoactivated  0.12 nM and 0.60 nM of conjugate samples are not significantly different from 
each other. It was encouraging to observe that even with the addition of conjugate at a higher 
concentration, the conjugate remained inert and caged and prevented the mineralization of 
hASCs in the scaffolds. The mineralization of scaffolds increased to 0.14 ± 0.08 and 0.12 ± 
0.003 for 0.60 nM and 0.12 nM conjugate samples respectively and the difference is statistically 
different from each other (p<0.05; one-sample t-test).  The increase in mineralization was a result 
of increasing the conjugate concentration and the number of hASC to 1.5 x 10
5
/scaffold. The 
statistically significant increase in mineralization of hASCs, with the addition of 0.60 nM of 
conjugate and higher cells, can potentially result in higher closure of the defect in vivo. We 
achieved 22.30 ± 4.93 percent closure of the CSD with 0.12 nM of activated conjugate but this 
percentage can potentially increase as higher concentration of conjugate and greater numbers of 
cells will mineralize the scaffold at a greater rate leading to an extended differentiation of hASCs 
to osteoblasts.  Additionally, we can correlate these results to the scaffolds implanted in vivo 
providing further evidence for the mineralization of the scaffolds implanted in the defects of 




Figure 4.7. The mineralization of hASCs was quantified by staining cells with Alizarin Red. § 
denotes significantly different values (p<0.05; one-sample t-test)  
 
4.5 Discussion  
Targeted delivery and controlled release of oligonucleotide therapeutics in vivo are 
essential aspects of an ideal gene delivery vehicle.[21] Delivery systems providing spatial and 
temporal control have the potential to improve outcomes in surgical reconstruction and 
regenerative medicine by precise modulation of wound healing and tissue repair processes. This 
photoactivated technique, particularly when combined with human autologous progenitor cells, 
may result in a new regenerative medicine paradigm. Modulation of gene expression with 
miRNA is a promising technique for improving control of wound healing and tissue repair 
processes. Recent efforts to modulate the osteogenic differentiation of human adipose derived 
MSC (ASC) were conducted in vitro and demonstrated the upregulation of early and late stage 
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osteogenic markers, alkaline phosphatase, osteocalcin, RUNX2 and Alizarin red staining when 
photoactivated. In this in vivo study we analyzed the healing of the critical size defect on the 
mouse calvarium with a particle system for delivery of a truncated miR-148b mimic[10]. 
We tested this technology on a well described critical size defect model[14] and observed 
interesting results. The 4 mm defect was drilled just off the sagittal midline to expose the left 
parietal bone and was healed with PCL scaffolds loaded with hASCs that were transfected with 
PC-miR-148b-SNP conjugates. PCL was chosen for this application as it has previously been 
demonstrated to have little impact on hASC differentiation.[22] The defect healed with the 
photoactivated conjugates while the control groups had minimal healing and remained opened 
even after 12 weeks, further verifying the model and the size of the non-healing defect. A 
progression was observed in the percent closure of the defect between 4 and 12 in all the samples 
but the sample size needs to be increased to conduct statistical analysis on the photoavtivated and 
non photoavtivated samples. The histological analysis on the decalcified calvarium sections also 
demonstrated the thickening of the collagen fiber lining, across the defect, when the 
photoavtivated conjugates were use. The collagen stained with HE and Masson‟s Trichome was 
on the same thickness as the pre-existing calvarium and the new bone was infused with older 
bone in the photoavtivated conjugates samples after 12 weeks.  
At 12 weeks, the percentage closure of the photoavtivated samples was not statistically 
different from the non photoavtivated samples and measures can be taken to improve the healing 
percentages. The combination of increasing the cell number and adding higher dosage of more 
purified conjugate samples can very likely increase the percent healing for photoactivated PC-
miR-148b conjugates while decreasing the percentages for non activated conjugates. This is 
hypothesized based on the results of ex vivo mineralization of scaffolds experiment. The Alizarin 
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Red absorbance increased from 0.12 ± 0.003 to 0.14 ± 0.08 (p<0.05; one-sample t-test) with the 
addition of higher dosage of conjugates. We believe that these improvements will also translate 
in our in vivo model and increase the closure of the defect to higher percentages to ones we 
achieved with 10 ul of conjugate and 1 x 10
5
 cells.  
To translate this technology into a clinical setting, better matrices or scaffolding materials 
need to be analyzed that have better activation of PC-miR- 148-SNP conjugate. The penetration 
depth of light across the scaffold is of major concern as it plays a critical role photoactivation of 
conjugates for the differentiation of hASCs.  
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Chapter 5. Conclusions and Future Work 
 
Targeted delivery and controlled release of oligonucleotide therapeutics in vivo are 
essential aspects of an ideal gene delivery vehicle.[1] Delivery systems providing spatial and 
temporal control have the potential to improve outcomes in surgical reconstruction and 
regenerative medicine by precise modulation of wound healing and tissue repair processes. This 
technique, particularly when combined with human autologous progenitor cells can result in a 
new regenerative medicine paradigm. Modulation of gene expression with microRNA (miRNA) 
is a promising technique for improving control of wound healing and tissue repair processes.[2] 
miRNAs are short, non-coding RNA‟s involved in post-transcriptional gene regulation. 
MicroRNA‟s utilized in modulating the differentiation of autologous, mesenchymal stromal/stem 
cells (MSC) are attractive as therapeutic modalities for regenerative medicine. Directing the 
osteogenic differentiation of these progenitors is of particular interest in the design of therapies 
for critical size bone defects, spinal fusion and skeletal reconstruction.  
5.1 Red-shifting the Photoactivation of Conjugates 
In future, nanoplasmonic particles as light activated gene delivery vehicles to provide 
improved spatial and temporal modulation of wound repair can be explored. The results in 
Chapter 2 and Chapter 3 demonstrate the modulation of osteogenic differentiation of human 
adipose derived MSC (ASC) both in vitro and in vivo using a murine critical sized defect model. 
A particle system for delivery of a truncated miR-148b mimic was developed, and demonstrated 
to be capable of upregulating the early and late stage osteogenic markers, alkaline phosphatase, 
osteocalcin, RUNX2 and Alizarin red staining when photoactivated.[3]  While these studies 
demonstrate the potential of light-regulated gene delivery for improving the spatial and temporal 
modulation of cell behavior, the application of this technology is limited by the narrow excitation 
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window in the UV region (~365nm). The visible and nIR activated nanoplasmonic miRNA 
delivery (vNAMD) system proposed herein is an improved gene delivery vector providing 
greater temporal and spatial control over the activation of miRNA based differentiation (Figure 
5.1). This photo-activated gene delivery system is composed of a metallic nanoparticle core or 
shell with a photo-absorbing element and a photocleavable miRNA payload.  The potential 
benefits of noble metal nanoparticles (NP) in delivery applications include readily tunable 
morphology, ease of bulk synthesis, large surface area-to-volume ratios and robust 
functionalization chemistries. Additionally, metal nanoparticles fulfill the core requirements as drug 




Figure 5.1 Overview of potential clinical implementation of visible and nIR activated 
nanoplasmonic miRNA delivery (vNAMD) system.  Injection of LAMD in critical bone defects, 
followed by targeted photoactivation induces differentiation at select sites, with minimal side 
effects such as heterotopic ossification. 
 144 
The particle morphology and composition can be tuned such that the localized surface 
plasmon resonance (LSPR) peak overlaps with the excitation maxima of the photo-responsive 
moiety in the payload resulting in photon energy specificity and high quantum efficiency for 
initiating cleavage. Previous studies have described both thermal and non-thermal components of 
plasmon mediated catalysis which can increase reaction rates by 2-3 orders of magnitude [5]. 
The non-thermal component is likely related to intense electrical fields in the oscillating surface 
plasmon region interacting with ionic molecules thus reducing the activation energy of the 
reaction.[5]  Metal enhanced fluorescence has been described with silver nanostructures, wherein 
a resonance state or coupled photon is shared between a photoactive molecule and the metal 
nanomaterial resulting in more efficient photoconversion.[6] In the case of the vNAMD these 
quantum mechanical surface plasmon events could result in significantly lowering the required 
photon flux and red-shifting the activation spectra, providing better tissue penetration, and 
reducing the photo-damage by transiting photons.  
A new photocleavable linking strategy for nucleic acids exploiting singlet oxygen 
cleavage of carbon-carbon bonds can be evaluated for visible and nIR range photomodulated 
payload release. In the proposed strategy commercially available photooxidizing compounds 
(used in PDT) with narrow excitation spectra, in the visible and nIR range, will be coupled to the 
nanoplasmonic metal particle via simple EDC chemistry with cysteamine self-assembled 
functional groups on the particle surface.  The particle will be back filled with a thiolated 
miRNA payload containing an olefin functionality (Figure 5.2). This electron rich carbon–carbon 
double bond is amenable to attack from the singlet oxygen produced via photooxidizer 
excitation.[7, 8] Using photooxidizing compounds, with discrete visible or nIR range activation 
energies, as the cleavage initiator allows multiple vNAMD to be developed with non-
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overlapping excitation spectra.  These vNAMD would allow clinicians to deliver several 
sequences of miRNA at the same time and activate them independently, both temporally and 
spatially, via narrow band or coherent light sources. This would allow progenitor cells in the 




Figure 5.2.  (I) Scheme for the functionalization of nanoparticles with porphyrin (Verteporfin). 
(II) The internal olefin cleavage site will be introduced via a base catalyzed Michael addition 
reaction between the 3‟ disulphide and hexynoic acid. The miRNA mimic construct with olefin 
group will then be coupled to the particle via EDC/NHS linkage with a self-assembled cystamine 
layer. (III) Diagram of vNAMD with red-shifted photoactivation (690nm) mechanism using 
singlet oxygen produced from a photosensitizer to cleave an electron rich  alkene bond on the 
miRNA payload. 
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The vNAMD platform possesses several unique advantages compared to the few 
previously described photoresponsive oligonucleotide delivery systems: 1) the miRNA payload 
can be activated with focused laser precision allowing activity only in the area of the tissue 
defect, and 2) because miRNA are labile, activity is transient resulting in pathway regulation 
only in the critical early stages of cell differentiation, 3) the vNAMD is photoresponsive in the 
visible and nIR range. This provides greater tissue penetration and reduced photon induced tissue 
damage compared to caging strategies utilizing UV photons.  Additionally, as the miRNA will 
only be transfected efficiently when bound to the particle, miRNA from vNAMD activated in the 
intercellular space will have little impact on surrounding tissue. This represents a paradigm shift 
from current methods of delivering osteogenic compounds such as diffusible BMP or BMP gene 
delivery where there is little spatial or temporal control of expression.  
5.2 Scaffold Alternates to PCL 
 
 PCL served as the matrix to hold the hASCs endocytosed with the PC-miR-48b-SNP 
conjugates during the in vivo study highlighted in Chapter 4. The penetration depth of light 
across the scaffold is of major concern as it plays a critical role photoactivation of conjugates for 
the differentiation of hASCs. PCL is a very dense material and the even at 1 mm thickness the 
light penetration is minimal. To achieve the best photo cleavage of the conjugates and allow this 
technology to transfer into clinical trials, a better matrix needs to be selected that can be loaded 
with hASCs, injected with conjugates and photoactivated with UV or NIR radiation.  
 We are working on few hydrogel based polymer systems that show better penetration 
depth comparatively. Matrigel, a BD Biosciences marketed product is a gelatinous protein 
mixture secreted by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells. Chilled Matrigel (4 
°C) exist as liquid and when incubated at 37 °C (body temperature) the Matrigel proteins self-
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assembles and gels into hydrogel. Traditionally it has been used as a screen drug molecule and is 
added to cells, morphological changes are observed.  
We stained the Matrigel with CMNB-caged carboxyfluorescein (5-carboxyfluorescein-
bis-(5-carboxymethoxy-2-nitrobenzyl) ether, alanine-carboxamide, succinimidyl ester) and 
uncaged with UV for 5 minutes (206nm). Figure 5.3 shows the ability of Matrigel to incubate a 
caged molecule that can be completely excited with UV radiation. The light penetration of 
Matrigel is also solved as the activated Matrigel appeared green (uncaged) while the uncaged 
Matrigel appeared blue (the color of the excited light). Studies are underway to analyze the 
ability of Matrigel to activate the PC-miR-148b-SNP conjugates and drive differentiation of 
hASCs by upregulating osteogenic markers (ALPL, OCN and RunX2). Also PC-miR-148b-SNP 




Figure 5.3. Caged-FITC labeled Matrigel, when activated, completely turns green when imaged 
under a microscope.      
 
5.3 Improve in vivo Results to Improve Healing of CSD  
 
In Chapter 4, the UV activation of the PC-miR148b-SNP conjugate released the miR-
148b and differentiated the hASCs in the scaffolds but the percentage healing of the defect with 
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photoactivated conjugates is lower than expected and can be further optimized to achieve higher 
closure of the defect. Also, the 12 weeks healing percentages of the experimental groups were 
not significantly different from each other. These in vivo results demonstrate a trend in the 
osteogenic differentiation of hASCs and formation of bone in the defect with the conjugates but 
the in vivo process of inducing osteogenic differentiation with these conjugates need to be 
optimized to achieve higher percent closure of the defect with the photoactivated conjugates. 
This will be achieved by increasing the number hASCs loaded to the scaffolds to 1.5 x 10
5 
cells/scaffold and increasing the number of mice for each experimental group to calculate the 
significant values.  
We also observed the defect treated with non photoactivated PC-miR148b-SNP 
conjugates to close to 10.91 ± 5.45% after 12 weeks and this can be reduced by proper handling 
of the scaffolds pre-implantation. For the next round of surgeries, special care was taken to 
minimize the light exposure during transporting the scaffold to surgery room and during the 
surgery to inhibit the release of miR-148b from the conjugates. The combination of increasing 
the cell number and additional purification, to remove the floating PC-miR-148b during the 
functionlization step, will very likely increase the percent healing for photoactivated PC-miR-
148b conjugates while decreasing the percentages for non activated conjugates.   
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